| 21573767 | Heterogeneous distribution of K-ras mutations in primary colon carcinomas: implications for EGFR-directed therapy. | Int J Colorectal Dis | 2011 Oct | Oltedal S | doi: 10.1007/s00384-011-1233-5 |
| 21884745 | Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence. | Hum Immunol | 2011 Nov | Kocian P | doi: 10.1016/j.humimm.2011.07.312 |
| 26631045 | MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS. | Tumour Biol | 2016 May | Fu X | doi: 10.1007/s13277-015-4507-7 |
| 26252055 | Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. | Cancer Biol Ther | 2015 | Buim ME | doi: 10.1080/15384047.2015.1070991 |
| 26959608 | Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. | Cell Cycle | 2016 | Lochhead PA | doi: 10.1080/15384101.2015.1120915. |
| 27857191 | Deregulation of the miR-16-KRAS axis promotes colorectal cancer. | Sci Rep | 2016 Nov 18 | You C | doi: 10.1038/srep37459. |
| 30809081 | Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. | World J Gastroenterol | 2019 Feb 21 | Wan XB | doi: 10.3748/wjg.v25.i7.808. |
| 29282362 | Genetic variants in the VEGF pathway as prognostic factors in stages II and III colon cancer. | Pharmacogenomics J | 2018 Jul | Riera P | doi: 10.1038/s41397-017-0009-x |
| 22198706 | The complex intratumoral heterogeneity of colon cancer highlighted by laser microdissection. | Dig Dis Sci | 2012 May | Buob D | doi: 10.1007/s10620-011-2023-1 |
| 18549880 | Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas. | Gastroenterology | 2008 Jun | Park SW | doi: 10.1053/j.gastro.2008.02.084 |
| 20628283 | Alcohol consumption and rectal tumor mutations and epigenetic changes. | Dis Colon Rectum | 2010 Aug | Slattery ML | doi: 10.1007/DCR.0b013e3181d325db. |
| 12606951 | LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. | Oncogene | 2003 Feb 27 | Li J | - |
| 25809746 | Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer. | J Thromb Haemost | 2015 Jun | Ades S | doi: 10.1111/jth.12910 |
| 24200637 | Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients. | Cancer Genet | 2013 Sep-Oct | Jiang L | doi: 10.1016/j.cancergen.2013.09.004 |
| 26352110 | KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases. | Pathology | 2015 Oct | Barresi V | doi: 10.1097/PAT.0000000000000300. |
| 22971512 | Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients. | J Int Med Res | 2012 | Li Z | - |
| 25491325 | KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer. | J Exp Clin Cancer Res | 2014 Dec 10 | Xu JM | doi: 10.1186/s13046-014-0104-7. |
| 20570890 | Genomic and biological characterization of exon 4 KRAS mutations in human cancer. | Cancer Res | 2010 Jul 15 | Janakiraman M | doi: 10.1158/0008-5472.CAN-10-0192 |
| 23240926 | Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series. | Thyroid | 2013 Jan | Ciampi R | doi: 10.1089/thy.2012.0207 |
| 21982684 | EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. | Cancer Lett | 2012 Jan 1 | Han CB | doi: 10.1016/j.canlet.2011.09.012 |
| 23027861 | Interplay between menin and K-Ras in regulating lung adenocarcinoma. | J Biol Chem | 2012 Nov 16 | Wu Y | doi: 10.1074/jbc.M112.382416 |
| 25541062 | AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. | Cancer Lett | 2015 Mar 1 | Kim EY | doi: 10.1016/j.canlet.2014.12.041 |
| 19372139 | The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras. | Carcinogenesis | 2009 Jun | Tsang WP | doi: 10.1093/carcin/bgp094 |
| 25687873 | Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer? | Cancer Res Treat | 2015 Oct | Kim ST | doi: 10.4143/crt.2014.106 |
| 22876876 | Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. | BMC Cancer | 2012 Aug 9 | Reinacher-Schick A | doi: 10.1186/1471-2407-12-349. |
| 21807965 | Progressive genomic instability in the FVB/Kras(LA2) mouse model of lung cancer. | Mol Cancer Res | 2011 Oct | To MD | doi: 10.1158/1541-7786.MCR-11-0219 |
| 22049925 | Tumor suppressor p16INK4a controls oncogenic K-Ras function in human pancreatic cancer cells. | Cancer Sci | 2012 Feb | Rabien A | doi: 10.1111/j.1349-7006.2011.02140.x |
| 26252300 | KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery. | Medicine (Baltimore) | 2015 Aug | Lee JW | doi: 10.1097/MD.0000000000001284. |
| 20098682 | Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. | PLoS One | 2010 Jan 21 | Lurkin I | doi: 10.1371/journal.pone.0008802. |
| 20682398 | Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. | Cancer Genet Cytogenet | 2010 Sep | Pehlivan S | doi: 10.1016/j.cancergencyto.2010.05.019. |
| 27270901 | Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. | Med Oncol | 2016 Jul | Li ZZ | doi: 10.1007/s12032-016-0787-z |
| 28025078 | Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer. | Hum Pathol | 2017 Apr | Reggiani Bonetti L | doi: 10.1016/j.humpath.2016.12.011 |
| 27346571 | High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis. | Hum Pathol | 2016 Oct | Watson R | doi: 10.1016/j.humpath.2016.06.010 |
| 26616862 | Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. | Oncogene | 2016 Jul 28 | Chu PC | doi: 10.1038/onc.2015.458 |
| 26333174 | MiR-622 inhibited colorectal cancer occurrence and metastasis by suppressing K-Ras. | Mol Carcinog | 2016 Sep | Fang Y | doi: 10.1002/mc.22380 |
| 27234640 | CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). | Ann Oncol | 2016 Aug | Michl M | doi: 10.1093/annonc/mdw222 |
| 28468801 | ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis. | Proc Natl Acad Sci U S A | 2017 May 16 | Hu L | doi: 10.1073/pnas.1617816114 |
| 28885658 | Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis. | Int J Biol Markers | 2017 Oct 31 | Tang M | doi: 10.5301/ijbm.5000295. |
| 30711927 | The Role of KRAS in Endometrial Cancer: A Mini-Review. | Anticancer Res | 2019 Feb | Sideris M | doi: 10.21873/anticanres.13145. |
| 30611220 | Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma. | BMC Cancer | 2019 Jan 5 | Choi MH | doi: 10.1186/s12885-018-5195-7. |
| 21811765 | Correlation between computed tomography findings and epidermal growth factor receptor and KRAS gene mutations in patients with pulmonary adenocarcinoma. | Oncol Rep | 2011 Nov | Sugano M | doi: 10.3892/or.2011.1412 |
| 27916952 | High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer. | Int J Mol Sci | 2016 Dec 1 | Jeantet M | - |
| 28665451 | Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? | Int J Biol Markers | 2017 Oct 31 | De Stefano A | doi: 10.5301/ijbm.5000273. |
| 18946061 | K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | N Engl J Med | 2008 Oct 23 | Karapetis CS | doi: 10.1056/NEJMoa0804385. |
| 16091732 | Dual effect of Kras(D12) knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy. | Oncogene | 2005 Dec 15 | Smakman N | - |
| 27630331 | Prediction of KRAS Mutation in Rectal Cancer Using MRI. | Anticancer Res | 2016 Sep | Shin YR | - |
| 23242173 | KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. | Virchows Arch | 2013 Jan | Dijkstra JR | doi: 10.1007/s00428-012-1356-2 |
| 24152947 | Pancreatic cancer: modulation of KRAS, MicroRNAs, and intercellular communication in the setting of tumor heterogeneity. | Pancreas | 2013 Nov | Lou E | doi: 10.1097/MPA.0000000000000007. |
| 23157823 | [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases]. | Zhonghua Bing Li Xue Za Zhi | 2012 Sep | Gao J | doi: 10.3760/cma.j.issn.0529-5807.2012.09.002. |
| 23528430 | Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology. | Exp Mol Pathol | 2013 Aug | Perez K | doi: 10.1016/j.yexmp.2013.01.004 |
| 17592266 | The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. | Am J Surg Pathol | 2007 Jul | Dehari R | - |
| 23157828 | [Correlation of KRAS gene mutations and clinicopathologic parameters in colorectal carcinoma]. | Zhonghua Bing Li Xue Za Zhi | 2012 Sep | Wang Q | doi: 10.3760/cma.j.issn.0529-5807.2012.09.007. |
| 28468669 | KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer. | BMC Cancer | 2017 May 3 | Kondo Y | doi: 10.1186/s12885-017-3305-6. |
| 27863403 | Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer. | Oncotarget | 2016 Dec 20 | Kidess-Sigal E | doi: 10.18632/oncotarget.13350. |
| 29445180 | Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion. | Nat Commun | 2018 Feb 14 | Marazioti A | doi: 10.1038/s41467-018-03051-z. |
| 29315556 | KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. | Int J Cancer | 2018 Jun 1 | Yang K | doi: 10.1002/ijc.31248 |
| 29027536 | KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome. | Mod Pathol | 2018 Feb | Zuo T | doi: 10.1038/modpathol.2017.121 |
| 30917791 | Impact of primary colorectal Cancer location on the KRAS status and its prognostic value. | BMC Gastroenterol | 2019 Mar 27 | Xie MZ | doi: 10.1186/s12876-019-0965-5. |
| 16482519 | Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. | Mol Carcinog | 2006 Jul | Floyd HS | - |
| 20627194 | Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. | Transl Res | 2010 Aug | Yokota T | doi: 10.1016/j.trsl.2010.05.007 |
| 25023700 | MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways. | Oncogene | 2015 May 14 | Patel A | doi: 10.1038/onc.2014.195 |
| 16257181 | Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. | Cell Signal | 2006 Aug | Dreissigacker U | - |
| 26868125 | Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. | BMC Cancer | 2016 Feb 11 | Cavalloni G | doi: 10.1186/s12885-016-2136-1. |
| 24440911 | Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma. | Cell Death Differ | 2014 May | Zhang Y | doi: 10.1038/cdd.2013.196 |
| 26393682 | The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth. | Oncotarget | 2015 Oct 20 | Hameiri-Grossman M | doi: 10.18632/oncotarget.5616. |
| 24139215 | The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. | Hum Pathol | 2013 Dec | Robertson S | doi: 10.1016/j.humpath.2013.07.026 |
| 22761399 | Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells. | Mol Cell Proteomics | 2012 Oct | Sudhir PR | - |
| 22927534 | Hurdles and complexities of codon 13 KRAS mutations. | J Clin Oncol | 2012 Oct 10 | Morelli MP | doi: 10.1200/JCO.2012.43.6535 |
| 17638924 | RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. | Carcinogenesis | 2007 Nov | Chow JY | - |
| 23619604 | KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. | Mod Pathol | 2013 Oct | Rekhtman N | doi: 10.1038/modpathol.2013.74 |
| 23112547 | MUC5AC/β-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors. | World J Gastroenterol | 2012 Oct 21 | Nakae K | doi: 10.3748/wjg.v18.i39.5551. |
| 19960433 | Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer. | Int J Cancer | 2010 Aug 1 | Dobrzycka B | doi: 10.1002/ijc.25077. |
| 12082617 | Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. | Oncogene | 2002 Jun 20 | Laghi L | - |
| 18834226 | CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. | Arch Pathol Lab Med | 2008 Oct | Lee S | doi: 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2. |
| 24742923 | Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine. | Oncotarget | 2014 Apr 30 | Wright GM | - |
| 24947996 | Targeting the K-Ras--JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation. | Oncotarget | 2014 Jul 15 | Okada M | - |
| 19789336 | RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. | Cancer Res | 2009 Oct 15 | Kreeger PK | doi: 10.1158/0008-5472.CAN-09-1921 |
| 23887305 | The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. | Mod Pathol | 2014 Feb | Kuhn E | doi: 10.1038/modpathol.2013.142 |
| 19893451 | Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. | Pancreas | 2009 Oct | Kubo T | doi: 10.1097/MPA.0b013e3181b8feb0. |
| 22138963 | Is KRAS mutation associated with interval colorectal cancers? | Dig Dis Sci | 2012 Apr | Shaukat A | doi: 10.1007/s10620-011-1974-6 |
| 18833187 | [K-ras mutations detection in paraaortic lymph nodes and its prognostic value after the surgical treatment of pancreas cancer]. | Khirurgiia (Mosk) | 2008 | Agaev BA | - |
| 25013125 | Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. | Clin Cancer Res | 2014 Sep 1 | Couraud S | doi: 10.1158/1078-0432.CCR-13-3063 |
| 16760301 | Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. | Ann Oncol | 2006 Jun | Bazan V | - |
| 24496383 | Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery. | Mol Ther | 2014 May | Mao CQ | doi: 10.1038/mt.2014.18 |
| 12651912 | Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo. | Mol Cancer Res | 2003 Mar | Long IS | - |
| 20675343 | The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. | Carcinogenesis | 2010 Oct | Zhao WG | doi: 10.1093/carcin/bgq160 |
| 18432074 | [K-ras mutation as a prognostic factor in colorectal carcinoma]. | Rozhl Chir | 2008 Jan | Sacha M | - |
| 25811077 | miR-134 functions as a tumor suppressor in cell proliferation and epithelial-to-mesenchymal Transition by targeting KRAS in renal cell carcinoma cells. | DNA Cell Biol | 2015 Jun | Liu Y | doi: 10.1089/dna.2014.2629 |
| 19888477 | Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. | PLoS One | 2009 Nov 4 | Kotoula V | doi: 10.1371/journal.pone.0007746. |
| 24263065 | KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer. | Br J Cancer | 2013 Dec 10 | Spindler KG | doi: 10.1038/bjc.2013.633 |
| 17707462 | High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. | Hum Pathol | 2007 Nov | Prall F | - |
| 26677873 | Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. | Proc Natl Acad Sci U S A | 2016 Jan 5 | Eng CH | doi: 10.1073/pnas.1515617113 |
| 17659731 | Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. | World J Gastroenterol | 2007 Jul 21 | Salek C | - |
| 21335545 | Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors. | Cancer Res | 2011 Mar 15 | Symonds JM | doi: 10.1158/0008-5472.CAN-10-1511 |
| 21873159 | Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells. | Anticancer Res | 2011 Jul | Tsunoda T | - |
| 23729268 | KRAS gene mutations in correlation with clinicopathological features of colorectal carcinomas in Indian patient cohort. | Med Oncol | 2013 | Patil H | doi: 10.1007/s12032-013-0617-5 |
| 26452035 | Deletion of cyclooxygenase-2 inhibits K-ras-induced lung carcinogenesis. | Oncotarget | 2015 Nov 17 | Pan Y | doi: 10.18632/oncotarget.5558. |
| 26267534 | Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes. | Cancer Cell | 2015 Aug 10 | Herrero A | doi: 10.1016/j.ccell.2015.07.001. |
| 24598028 | The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells. | BMC Cancer | 2014 Mar 6 | Leibovich-Rivkin T | doi: 10.1186/1471-2407-14-158. |
| 25137394 | KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. | PLoS One | 2014 Aug 19 | Kalikaki A | doi: 10.1371/journal.pone.0104902 |
| 22441881 | Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx. | Int J Clin Oncol | 2013 Jun | Fujii S | doi: 10.1007/s10147-012-0402-z |
| 25946211 | Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer. | PLoS One | 2015 May 6 | Danese E | doi: 10.1371/journal.pone.0126417 |
| 23157826 | [Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas]. | Zhonghua Bing Li Xue Za Zhi | 2012 Sep | Gao J | doi: 10.3760/cma.j.issn.0529-5807.2012.09.005. |
| 16575407 | Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis. | Cell Death Differ | 2006 Nov | Lin L | - |
| 22589270 | A comprehensive survey of Ras mutations in cancer. | Cancer Res | 2012 May 15 | Prior IA | doi: 10.1158/0008-5472.CAN-11-2612. |
| 24998492 | Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation. | Hum Pathol | 2014 Sep | Hershkovitz D | doi: 10.1016/j.humpath.2014.05.005 |
| 21408138 | Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. | PLoS One | 2011 Mar 8 | van Eijk R | doi: 10.1371/journal.pone.0017791. |
| 20512148 | DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS. | Nat Struct Mol Biol | 2010 Jun | Lauth M | doi: 10.1038/nsmb.1833 |
| 22588152 | A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. | J Thorac Oncol | 2012 Jun | Cuffe S | doi: 10.1097/JTO.0b013e31824fe9e6. |
| 20565773 | SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. | BMC Cancer | 2010 Jun 17 | Sameer AS | doi: 10.1186/1471-2407-10-300. |
| 25133424 | Menin determines K-RAS proliferative outputs in endocrine cells. | J Clin Invest | 2014 Sep | Chamberlain CE | doi: 10.1172/JCI69004 |
| 19995707 | Mutations in the KRAS gene in ovarian tumors. | Folia Histochem Cytobiol | 2009 | Dobrzycka B | doi: 10.2478/v10042-009-0039-6. |
| 25798815 | Expression of KRASG12V in Zebrafish Gills Induces Hyperplasia and CXCL8-Associated Inflammation. | Zebrafish | 2015 Jun | Shive HR | doi: 10.1089/zeb.2014.1038 |
| 19101897 | Mutations of RAS gene family in specimens of bladder cancer. | Urol J | 2008 Fall | Karimianpour N | - |
| 22247021 | Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. | J Natl Cancer Inst | 2012 Feb 8 | Ihle NT | doi: 10.1093/jnci/djr523 |
| 21055216 | [K-ras gene mutation in colorectal cancer and its clinicopathologic significance]. | Zhonghua Wai Ke Za Zhi | 2010 Aug 15 | Yuan Y | - |
| 22222375 | RAS oncogenic signal upregulates EZH2 in pancreatic cancer. | Biochem Biophys Res Commun | 2012 Jan 20 | Fujii S | doi: 10.1016/j.bbrc.2011.12.099 |
| 26560143 | Absolute Quantification of Endogenous Ras Isoform Abundance. | PLoS One | 2015 Nov 11 | Mageean CJ | doi: 10.1371/journal.pone.0142674 |
| 21825899 | Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. | Dis Colon Rectum | 2011 Sep | Watanabe T | doi: 10.1097/DCR.0b013e31821d37a3. |
| 22706026 | Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. | J Mol Biol | 2012 Sep 28 | Spangler JB | doi: 10.1016/j.jmb.2012.06.014 |
| 22708448 | [Age-related and clinical-pathogenetic features of colorectal cancer associated with status of K-ras gene]. | Adv Gerontol | 2012 | Beliaeva AV | - |
| 27062566 | KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer. | Cancer Biomark | 2016 Mar 4 | Ribeiro KB | doi: 10.3233/CBM-160592. |
| 26902163 | Variation in KRAS driver substitution distributions between tumor types is determined by both mutation and natural selection. | Sci Rep | 2016 Feb 23 | Ostrow SL | doi: 10.1038/srep21927. |
| 21332555 | Analysis of K-ras, BRAF, and PIK3CA mutations in laterally-spreading tumors of the colorectum. | J Gastroenterol Hepatol | 2011 Mar | Kaji E | doi: 10.1111/j.1440-1746.2010.06485.x. |
| 24368337 | The proto-oncogene KRAS is targeted by miR-200c. | Oncotarget | 2014 Jan 15 | Kopp F | - |
| 22427190 | Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. | Int J Biol Markers | 2012 Jan-Mar | Bagadi SB | doi: 10.5301/JBM.2012.9108. |
| 26837759 | Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia. | Cancer Res | 2016 Apr 15 | Prieto C | doi: 10.1158/0008-5472.CAN-15-2769 |
| 25341034 | RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. | Cell Death Dis | 2014 Oct 23 | Kang R | doi: 10.1038/cddis.2014.445. |
| 26684859 | Alterations in Tumor DNA Are Related to Short Postoperative Survival in Patients Resected for Pancreatic Carcinoma Aimed at Cure. | Pancreas | 2016 Jul | Asting AG | doi: 10.1097/MPA.0000000000000566. |
| 27345584 | Targeting the serrated pathway of colorectal cancer with mutation in BRAF. | Biochim Biophys Acta | 2016 Aug | Matos P | doi: 10.1016/j.bbcan.2016.06.003 |
| 27550813 | Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer. | Mol Cell Biol | 2016 Oct 13 | Zhong X | doi: 10.1128/MCB.00079-16 |
| 26279302 | Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer. | Oncogene | 2016 May 12 | Zhang S | doi: 10.1038/onc.2015.306 |
| 27041569 | AMPK promotes tolerance to Ras pathway inhibition by activating autophagy. | Oncogene | 2016 Oct 6 | Sanduja S | doi: 10.1038/onc.2016.70 |
| 28697193 | The value of 18FDG PET/CT parameters, hematological parameters and tumor markers in predicting KRAS oncogene mutation in colorectal cancer. | Hell J Nucl Med | 2017 May-Aug | Oner AO | doi: 10.1967/s002449910557 |
| 28188750 | KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior. | Hum Pathol | 2017 Jul | Jang S | doi: 10.1016/j.humpath.2017.01.010 |
| 28619714 | The G protein-coupled receptor GPR31 promotes membrane association of KRAS. | J Cell Biol | 2017 Aug 7 | Fehrenbacher N | doi: 10.1083/jcb.201609096 |
| 28699162 | Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas. | Int J Cancer | 2017 Nov 1 | Dietz S | doi: 10.1002/ijc.30881 |
| 28867179 | RAGE maintains high levels of NFκB and oncogenic Kras activity in pancreatic cancer. | Biochem Biophys Res Commun | 2017 Nov 4 | Azizan N | doi: 10.1016/j.bbrc.2017.08.147 |
| 28188683 | Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. | Mol Oncol | 2017 Apr | Polosukhina D | doi: 10.1002/1878-0261.12044 |
| 29175303 | EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies. | Exp Mol Pathol | 2017 Dec | Forest F | doi: 10.1016/j.yexmp.2017.11.013 |
| 27382031 | Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. | Oncologist | 2016 Aug | Moretto R | doi: 10.1634/theoncologist.2016-0084 |
| 29246442 | Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. | Immunity | 2017 Dec 19 | Coelho MA | doi: 10.1016/j.immuni.2017.11.016 |
| 27447549 | Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. | Oncotarget | 2016 Aug 16 | Muller Y | doi: 10.18632/oncotarget.10658. |
| 27888800 | Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms. | Oncotarget | 2016 Dec 13 | Lee YJ | doi: 10.18632/oncotarget.13449. |
| 27999210 | LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. | Oncotarget | 2017 Feb 7 | Vakana E | doi: 10.18632/oncotarget.14002. |
| 28096270 | Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. | Clin Cancer Res | 2017 Jul 15 | Fujii T | doi: 10.1158/1078-0432.CCR-16-2592 |
| 29203670 | Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous. | Proc Natl Acad Sci U S A | 2017 Dec 19 | Chung WJ | doi: 10.1073/pnas.1708391114 |
| 28708207 | Variations in transrenal DNA and comparison with plasma DNA as a diagnostic marker for colorectal cancer. | Int J Biol Markers | 2017 Oct 31 | Tian F | doi: 10.5301/ijbm.5000288. |
| 29115540 | MicroRNA-326 inhibits melanoma progression by targeting KRAS and suppressing the AKT and ERK signalling pathways. | Oncol Rep | 2018 Jan | Kang K | doi: 10.3892/or.2017.6074 |
| 29103773 | KRAS mutation and immunohistochemical profile in intraductal papillary neoplasm of the intrahepatic bile ducts. | Pathol Res Pract | 2018 Jan | Xian ZH | doi: 10.1016/j.prp.2017.10.017 |
| 30013058 | In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. | Nat Commun | 2018 Jul 16 | Grzeskowiak CL | doi: 10.1038/s41467-018-04572-3. |
| 29104111 | Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis. | Hum Pathol | 2018 Jan | Mamoori A | doi: 10.1016/j.humpath.2017.10.024 |
| 29358307 | miR-422a inhibits osteosarcoma proliferation by targeting BCL2L2 and KRAS. | Biosci Rep | 2018 Mar 21 | Zhang H | doi: 10.1042/BSR20170339 |
| 29240583 | Site-specific Differences in Colonic Adenocarcinoma: KRAS Mutations and High Tumor Budding Are More Frequent in Cecal Adenocarcinoma. | Am J Surg Pathol | 2018 Mar | Landau MA | doi: 10.1097/PAS.0000000000001004. |
| 22833420 | Epidermal growth factor receptor and Kras gene expression: reliability of mutational analysis on cytological samples. | Diagn Cytopathol | 2013 Jul | Bozzetti C | doi: 10.1002/dc.22905 |
| 26722374 | Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells. | Theranostics | 2016 Jan 1 | Clark DJ | doi: 10.7150/thno.12350 |
| 27461636 | rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis. | J Cancer Res Ther | 2016 Apr-Jun | Zhang SY | doi: 10.4103/0973-1482.147379. |
| 25633745 | Activation of KRAS promotes the mesenchymal features of basal-type breast cancer. | Exp Mol Med | 2015 Jan 30 | Kim RK | doi: 10.1038/emm.2014.99. |
| 24861525 | Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer. | Rev Gastroenterol Mex | 2014 Apr-Jun | Palacio-Rua KA | doi: 10.1016/j.rgmx.2014.05.001 |
| 23558076 | Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS. | Hepatobiliary Pancreat Dis Int | 2013 Apr | Duan YF | - |
| 24467518 | Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status. | Curr Cancer Drug Targets | 2014 | Shi M | - |
| 26376292 | Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers. | Int J Cancer | 2016 Mar 1 | de Cuba EM | doi: 10.1002/ijc.29855 |
| 24259266 | KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer. | Int J Cancer | 2014 Jun 15 | Kohonen-Corish MR | doi: 10.1002/ijc.28619 |
| 21385923 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. | Clin Cancer Res | 2011 Jun 1 | Pharoah PD | doi: 10.1158/1078-0432.CCR-10-3405 |
| 24331409 | KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. | Lung Cancer | 2014 Feb | Maus MK | doi: 10.1016/j.lungcan.2013.11.010 |
| 27096769 | K-ras gene mutation as an early prognostic marker of colon cancer. | Pol Przegl Chir | 2016 Jan 1 | Szpon | doi: 10.1515/pjs-2016-0021. |
| 24694877 | Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting Akt and Sonic hedgehog pathways. | PLoS One | 2014 Apr 2 | Huang M | doi: 10.1371/journal.pone.0092161 |
| 14761400 | [Co-detection of P21, P53 and HSP70 and their possible role in diagnosis of polycyclic aromatic hydrocarbons (PAHs)-related lung cancer]. | Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi | 2003 Oct | Lu QF | - |
| 25158139 | Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations. | Int J Environ Res Public Health | 2014 Aug 25 | Yilmaz A | doi: 10.3390/ijerph110908645. |
| 25002494 | Ras transformation uncouples the kinesin-coordinated cellular nutrient response. | Proc Natl Acad Sci U S A | 2014 Jul 22 | Zaganjor E | doi: 10.1073/pnas.1411016111 |
| 25713893 | Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer. | Hepatogastroenterology | 2014 Oct | Chang YY | - |
| 24021343 | p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. | Radiother Oncol | 2013 Oct | Gilbert DC | doi: 10.1016/j.radonc.2013.08.002 |
| 25450872 | Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer. | Clin Lung Cancer | 2015 Jan | Mak RH | doi: 10.1016/j.cllc.2014.09.005 |
| 25137136 | Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer. | PLoS One | 2014 Aug 19 | Wang L | doi: 10.1371/journal.pone.0104282 |
| 24394008 | [Analysis of KRAS status in cancer tissue with submucosal or deeper invasion in patients with familial adenomatous polyposis]. | Gan To Kagaku Ryoho | 2013 Nov | Tajima Y | - |
| 27573925 | Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors. | Mol Med Rep | 2016 Oct | Bidinotto LT | doi: 10.3892/mmr.2016.5684 |
| 28259994 | Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer. | Int J Mol Med | 2017 Apr | Bai S | doi: 10.3892/ijmm.2017.2903 |
| 27182622 | KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients. | Mol Carcinog | 2017 Feb | Gao W | doi: 10.1002/mc.22501 |
| 27312358 | The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy. | Mol Carcinog | 2017 Feb | Matsunaga Y | doi: 10.1002/mc.22513 |
| 28139399 | Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. | Pancreatology | 2017 Mar - Apr | Ako S | doi: 10.1016/j.pan.2016.12.011 |
| 28710768 | Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ. | Int J Cancer | 2017 Nov 1 | Lee WY | doi: 10.1002/ijc.30888 |
| 27477280 | Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. | Cell Rep | 2016 Aug 9 | Padanad MS | doi: 10.1016/j.celrep.2016.07.009 |
| 28475173 | MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1. | Cell Death Differ | 2017 Jul | Shen H | doi: 10.1038/cdd.2017.63 |
| 29246726 | K-ras mutation promotes ionizing radiation-induced invasion and migration of lung cancer in part via the Cathepsin L/CUX1 pathway. | Exp Cell Res | 2018 Jan 15 | Wang L | doi: 10.1016/j.yexcr.2017.12.006 |
| 30018674 | Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer. | Dis Markers | 2018 Jun 19 | Reggiani Bonetti L | doi: 10.1155/2018/2959801 |
| 30171261 | mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. | Oncogene | 2019 Jan | Liang SQ | doi: 10.1038/s41388-018-0479-6 |
| 30394984 | A Changing Spectrum of Colorectal Cancer Biology With Age: Implications for the Young Patient. | Dis Colon Rectum | 2019 Jan | Chouhan H | doi: 10.1097/DCR.0000000000001188. |
| 21645454 | [Study on point mutations of K-ras gene in non-small cell lung cancer in Guangxi]. | Zhongguo Fei Ai Za Zhi | 2011 Jun | Zhong W | doi: 10.3779/j.issn.1009-3419.2011.06.06. |
| 20619739 | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. | Lancet Oncol | 2010 Aug | De Roock W | doi: 10.1016/S1470-2045(10)70130-3 |
| 22337533 | Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. | Cancer Epidemiol Biomarkers Prev | 2012 Apr | Limburg PJ | doi: 10.1158/1055-9965.EPI-11-1168 |
| 14601056 | Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer. | Int J Cancer | 2003 Dec 20 | Uchiyama M | - |
| 23134218 | MicroRNA let-7a inhibits the proliferation and invasion of nonsmall cell lung cancer cell line 95D by regulating K-Ras and HMGA2 gene expression. | Cancer Biother Radiopharm | 2013 Mar | Wang YY | doi: 10.1089/cbr.2012.1307 |
| 26575954 | Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras. | Oncotarget | 2015 Dec 1 | Sung S | doi: 10.18632/oncotarget.6334. |
| 23075074 | Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. | Cancer Invest | 2012 Dec | Han CB | doi: 10.3109/07357907.2012.732159 |
| 26902995 | The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B. | Sci Rep | 2016 Feb 23 | Lu S | doi: 10.1038/srep21949. |
| 24888607 | Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non-small-cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. | J Surg Oncol | 2014 Sep | Kim TJ | doi: 10.1002/jso.23646 |
| 26477488 | The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways. | Biochim Biophys Acta | 2015 Dec | Vasseur R | doi: 10.1016/j.bbagrm.2015.10.014 |
| 26891420 | A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. | Int J Cancer | 2016 Jul 1 | Eng C | doi: 10.1002/ijc.30049 |
| 21544811 | Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. | Int J Cancer | 2012 Apr 15 | Sunaga N | doi: 10.1002/ijc.26164 |
| 24727325 | Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). | Clin Cancer Res | 2014 Jun 15 | Sha D | doi: 10.1158/1078-0432.CCR-14-0069 |
| 22848379 | Sensitization of human pancreatic cancer cells harboring mutated K-ras to apoptosis. | PLoS One | 2012 | Shen L | doi: 10.1371/journal.pone.0040435 |
| 24861917 | Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. | Med Oncol | 2014 Jul | Zhu K | doi: 10.1007/s12032-014-0016-6 |
| 25444464 | Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. | Clin Colorectal Cancer | 2014 Dec | Cercek A | doi: 10.1016/j.clcc.2014.09.001 |
| 22983505 | Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. | J Gastroenterol | 2013 May | Ogura T | doi: 10.1007/s00535-012-0664-2 |
| 25609577 | KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. | J Clin Pathol | 2015 Apr | Malapelle U | doi: 10.1136/jclinpath-2014-202761 |
| 22245873 | Role of oncogenic pathways and KRAS/BRAF mutations in the behavior of colon adenocarcinoma in renal transplant patients. | Transplantation | 2012 Mar 15 | Revuelta I | doi: 10.1097/TP.0b013e318242be46. |
| 22459936 | KRAS and BRAF mutations in sinonasal cancer. | Oral Oncol | 2012 Aug | Lopez F | doi: 10.1016/j.oraloncology.2012.02.018 |
| 26977001 | The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy. | Anticancer Res | 2016 Mar | Svaton M | - |
| 26400062 | Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients. | Cancer Res | 2015 Nov 15 | Wright KL | doi: 10.1158/0008-5472.CAN-14-2992 |
| 24700299 | The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study. | Ann Surg Oncol | 2014 Aug | Abdul-Jalil KI | doi: 10.1245/s10434-014-3658-x |
| 21678640 | [Identification of K-RAS mutations in colorectal cancer patients in Israel]. | Harefuah | 2011 May | Segal G | - |
| 23026567 | Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells. | J Thorac Cardiovasc Surg | 2012 Dec | Yu JA | doi: 10.1016/j.jtcvs.2012.08.064 |
| 26921316 | Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells. | J Biol Chem | 2016 Apr 22 | Patel D | doi: 10.1074/jbc.M115.710145 |
| 25155261 | KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis. | Colorectal Dis | 2014 Nov | Li W | doi: 10.1111/codi.12749. |
| 20647319 | A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. | Cancer Res | 2010 Aug 15 | Ratner E | doi: 10.1158/0008-5472.CAN-10-0689 |
| 22541434 | The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. | Cell | 2012 Apr 27 | Kumar MS | doi: 10.1016/j.cell.2012.02.059. |
| 23161513 | Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. | Mol Cell Proteomics | 2013 Feb | Demory Beckler M | doi: 10.1074/mcp.M112.022806 |
| 26840022 | KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. | Oncotarget | 2016 Feb 16 | Pan W | doi: 10.18632/oncotarget.7080. |
| 24889488 | KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. | Ann Surg Oncol | 2015 Jan | Lee DW | doi: 10.1245/s10434-014-3826-z |
| 24811330 | KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at? | Asia Pac J Clin Oncol | 2014 Sep | Scott RJ | doi: 10.1111/ajco.12201 |
| 20559151 | Prognostic implications of epidermal growth factor receptor and KRAS gene mutations and epidermal growth factor receptor gene copy numbers in patients with surgically resectable non-small cell lung cancer in Taiwan. | J Thorac Oncol | 2010 Aug | Liu HP | doi: 10.1097/JTO.0b013e3181e2f4d6. |
| 24774510 | Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. | BMC Res Notes | 2014 Apr 29 | Takahashi N | doi: 10.1186/1756-0500-7-271. |
| 20571907 | PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. | Mol Biol Rep | 2011 Feb | Herreros-Villanueva M | doi: 10.1007/s11033-010-0236-6 |
| 21949883 | Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. | PLoS One | 2011 | Santis G | doi: 10.1371/journal.pone.0025191 |
| 25713627 | Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. | J Med Life | 2014 Oct-Dec | Dinu D | - |
| 23236152 | Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. | Proc Natl Acad Sci U S A | 2012 Dec 26 | Weng MT | doi: 10.1073/pnas.1207673110 |
| 22982650 | Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). | J Thorac Oncol | 2012 Oct | Cadranel J | - |
| 27037031 | Systematic review: brain metastases from colorectal cancer--Incidence and patient characteristics. | BMC Cancer | 2016 Apr 1 | Christensen TD | doi: 10.1186/s12885-016-2290-5. |
| 23111797 | [The change of pathology in the era of personalized medicine using the example of discordant KRAS mutational status in metastasized colorectal carcinoma]. | Dtsch Med Wochenschr | 2012 Nov | Hekeler E | doi: 10.1055/s-0032-1327249 |
| 21550229 | A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. | Eur J Cancer | 2011 Jun | Adelstein BA | doi: 10.1016/j.ejca.2011.03.031 |
| 25183481 | A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. | Clin Cancer Res | 2014 Sep 1 | Saridaki Z | doi: 10.1158/1078-0432.CCR-14-0348. |
| 21298467 | Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. | Eur J Epidemiol | 2011 Mar | Parker LA | doi: 10.1007/s10654-011-9547-8 |
| 23657052 | KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. | Jpn J Clin Oncol | 2013 Jul | Watanabe T | doi: 10.1093/jjco/hyt062 |
| 23885463 | [Correlation between the presence of Kras mutation and the presence of the proteins epiregulin and amphiregulin in colon cancer tissue]. | Harefuah | 2013 Jun | Levi Y | - |
| 25248721 | Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer. | Pathol Oncol Res | 2015 Apr | Docs O | doi: 10.1007/s12253-014-9834-2 |
| 16953233 | KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. | Oncogene | 2007 Jan 4 | Oliveira C | - |
| 23849768 | Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. | Pathol Biol (Paris) | 2013 Dec | Marchoudi N | doi: 10.1016/j.patbio.2013.05.004 |
| 23821376 | Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. | Target Oncol | 2014 Jun | Di Bartolomeo M | doi: 10.1007/s11523-013-0283-8 |
| 23264394 | Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. | J Clin Endocrinol Metab | 2013 Feb | Agrawal N | doi: 10.1210/jc.2012-2703 |
| 12372883 | p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer. | Urol Int | 2002 | Jankevicius F | - |
| 24595526 | Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa). | Virchows Arch | 2014 May | Fu M | doi: 10.1007/s00428-014-1566-x |
| 24806883 | Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. | Oncol Rep | 2014 Jul | Ogura T | doi: 10.3892/or.2014.3165 |
| 20421765 | Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. | J Thorac Oncol | 2010 May | Smit EF | doi: 10.1097/JTO.0b013e3181d86ebf. |
| 26723875 | The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib. | Cancer Lett | 2016 Mar 1 | Park KS | doi: 10.1016/j.canlet.2015.12.015 |
| 24522420 | [KRAS gene mutation in colorectal cancer]. | Rev Med Chil | 2013 Sep | Roa I | doi: 10.4067/S0034-98872013000900009. |
| 19378369 | KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors. | Clin Adv Hematol Oncol | 2008 Dec | Lenz HJ | - |
| 23188063 | Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. | Int J Clin Oncol | 2013 Dec | Nakanishi R | doi: 10.1007/s10147-012-0501-x |
| 20010090 | Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. | Ann Surg | 2010 Feb | Yen LC | doi: 10.1097/SLA.0b013e3181bc9d96. |
| 25851630 | Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. | Ann Oncol | 2015 Aug | Normanno N | doi: 10.1093/annonc/mdv176 |
| 18289366 | K-ras mutations in sinonasal cancers in relation to wood dust exposure. | BMC Cancer | 2008 Feb 20 | Bornholdt J | doi: 10.1186/1471-2407-8-53. |
| 22436609 | KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. | BMC Cancer | 2012 Mar 22 | Cerne JZ | doi: 10.1186/1471-2407-12-105. |
| 22583358 | K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma. | APMIS | 2012 Jun | Mannan A | doi: 10.1111/j.1600-0463.2011.02852.x |
| 25691052 | Activation of RAS family members confers resistance to ROS1 targeting drugs. | Oncotarget | 2015 Mar 10 | Cargnelutti M | - |
| 25778332 | Association of rs712 polymorphism in Kras gene 3'-luntranslated region and cancer risk: a meta-analysis. | J BUON | 2015 Jan-Feb | Zhao WH | - |
| 23908594 | Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems. | Neoplasia | 2013 Aug | Nagaria TS | - |
| 23724098 | Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. | PLoS One | 2013 May 28 | Sun JM | doi: 10.1371/journal.pone.0064816 |
| 23307237 | Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? | Med Oncol | 2013 Mar | Kim ST | doi: 10.1007/s12032-012-0328-3 |
| 21364589 | Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. | Br J Cancer | 2011 Mar 15 | Rachagani S | doi: 10.1038/bjc.2011.31 |
| 15943410 | APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance. | Am Surg | 2005 Apr | Hsieh JS | - |
| 21073737 | Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes. | Mol Cancer | 2010 Nov 13 | Chun SY | doi: 10.1186/1476-4598-9-293. |
| 19639197 | Mutation detection of KRAS by high-resolution melting analysis in Chinese with gastric cancer. | Oncol Rep | 2009 Sep | Liu ZM | - |
| 22213982 | [Clinical significance and the handling of KRAS testing on metastatic colorectal cancer]. | Nihon Rinsho | 2011 Apr | Kawamoto Y | - |
| 19843849 | Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. | Cancer Res | 2009 Nov 1 | Kikuchi H | doi: 10.1158/0008-5472.CAN-09-2213 |
| 24297898 | Mutant KRAS is a druggable target for pancreatic cancer. | Proc Natl Acad Sci U S A | 2013 Dec 17 | Zorde Khvalevsky E | doi: 10.1073/pnas.1314307110 |
| 26799289 | Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis. | Oncotarget | 2016 Feb 16 | Fritsche-Guenther R | doi: 10.18632/oncotarget.6959. |
| 22613949 | Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. | Cell Res | 2012 Aug | Steckel M | doi: 10.1038/cr.2012.82 |
| 25997687 | RAS status in Korean patients with stage III and IV colorectal cancer. | Clin Transl Oncol | 2015 Sep | Lee WS | doi: 10.1007/s12094-015-1301-3 |
| 18614859 | Shining the spotlight on shed KRAS in pancreatic cancer. | Cancer Biol Ther | 2008 Mar | Sempere LF | - |
| 26789109 | Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer. | Oncotarget | 2016 Feb 16 | Li W | doi: 10.18632/oncotarget.6671. |
| 22948721 | Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. | Oncology | 2012 | Modest DP | - |
| 26055143 | Association of CCND1 overexpression with KRAS and PTEN alterations in specific subtypes of non-small cell lung carcinoma and its influence on patients' outcome. | Tumour Biol | 2015 Nov | Dragoj M | doi: 10.1007/s13277-015-3620-y |
| 25253780 | Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancers. | Mol Cancer Ther | 2014 Dec | Mittal S | doi: 10.1158/1535-7163.MCT-14-0280 |
| 26725968 | Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer. | Mol Oncol | 2016 Apr | Tjensvoll K | doi: 10.1016/j.molonc.2015.11.012 |
| 27221845 | Correlation between RAS Test Results and Prognosis of Metastatic Colorectal Cancer Patients: a Report from Western Iran. | Asian Pac J Cancer Prev | 2016 | Payandeh M | - |
| 23376846 | Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia. | Oncogene | 2014 Feb 13 | Ray KC | doi: 10.1038/onc.2013.3 |
| 20100685 | KRAS mutation screening in colorectal cancer: From paper to practice. | Clin Colorectal Cancer | 2010 Jan | Fakih MM | doi: 10.3816/CCC.2010.n.003. |
| 20645028 | Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. | Med Oncol | 2011 Dec | Licar A | doi: 10.1007/s12032-010-9631-z |
| 18075308 | Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. | Cancer Biol Ther | 2008 Mar | Shi C | - |
| 22528563 | EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. | Cell Oncol (Dordr) | 2012 Jun | Smits AJ | doi: 10.1007/s13402-012-0078-4 |
| 20959479 | Identification of susceptibility loci in a mouse model of KRASG12D-driven pancreatic cancer. | Cancer Res | 2010 Nov 1 | Jorgenson TC | doi: 10.1158/0008-5472.CAN-09-3980 |
| 23630215 | Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. | J Clin Oncol | 2013 Jun 10 | Shepherd FA | doi: 10.1200/JCO.2012.48.1390 |
| 23564819 | Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. | Anticancer Res | 2013 Apr | Fiala O | - |
| 25305448 | Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/β-catenin signaling pathway. | Cancer Lett | 2015 Jan 28 | Xu W | doi: 10.1016/j.canlet.2014.10.008 |
| 25427581 | Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. | Oncol Res Treat | 2014 | Brunner S | doi: 10.1159/000368313 |
| 15923428 | Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. | Ann Oncol | 2005 May | Russo A | - |
| 19546608 | KRAS mutation testing in colorectal cancer. | Adv Anat Pathol | 2009 Jul | Plesec TP | doi: 10.1097/PAP.0b013e3181a9d4ed. |
| 25864038 | KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. | Mol Oncol | 2015 Aug | Deng Y | doi: 10.1016/j.molonc.2015.03.006 |
| 23806795 | Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist? | Lung Cancer | 2013 Sep | Bauml J | doi: 10.1016/j.lungcan.2013.05.011 |
| 26049686 | Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. | Eur J Cancer | 2015 Sep | Peeters M | doi: 10.1016/j.ejca.2015.05.017 |
| 19137007 | Role of miR-143 targeting KRAS in colorectal tumorigenesis. | Oncogene | 2009 Mar 12 | Chen X | doi: 10.1038/onc.2008.474 |
| 21483104 | Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. | Anal Cell Pathol (Amst) | 2011 | Richman SD | doi: 10.3233/ACP-2011-0005. |
| 25245423 | MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. | Oncotarget | 2014 Oct 15 | Kharbanda A | - |
| 21795973 | Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. | Anticancer Drugs | 2011 Oct | Modest DP | doi: 10.1097/CAD.0b013e3283493160. |
| 20233436 | Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. | BMC Cancer | 2010 Mar 16 | Naguib A | doi: 10.1186/1471-2407-10-99. |
| 17198183 | K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. | Pancreas | 2007 Jan | Jiao L | - |
| 22586484 | KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. | PLoS One | 2012 | Mao C | doi: 10.1371/journal.pone.0036653 |
| 19824059 | Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. | J Pathol | 2009 Dec | Abubaker J | doi: 10.1002/path.2625. |
| 26299805 | Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. | Oncotarget | 2015 Aug 28 | Morkel M | - |
| 15534934 | Co-mutation of p53, K-ras genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. | World J Gastroenterol | 2004 Dec 15 | Pan ZZ | - |
| 24715238 | Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen. | Int J Oncol | 2014 Jun | Bruera G | doi: 10.3892/ijo.2014.2369 |
| 19603024 | Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. | Br J Cancer | 2009 Aug 4 | Souglakos J | doi: 10.1038/sj.bjc.6605164 |
| 22082529 | Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells. | Cancer Lett | 2012 Mar | Yoon YK | doi: 10.1016/j.canlet.2011.10.023 |
| 24349411 | Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers. | PLoS One | 2013 Dec 12 | Kleiman LB | doi: 10.1371/journal.pone.0082982 |
| 24675495 | Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia. | Tumori | 2014 Jan-Feb | Zahrani A | doi: 10.1700/1430.15819. |
| 23975373 | A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. | Tumour Biol | 2014 Jan | Pan XM | doi: 10.1007/s13277-013-1114-3 |
| 19678923 | Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer. | BMC Cancer | 2009 Aug 13 | Mlakar V | doi: 10.1186/1471-2407-9-282. |
| 27100819 | Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. | JAMA Oncol | 2016 Jun 1 | Wood K | doi: 10.1001/jamaoncol.2016.0405. |
| 22988093 | Selective requirement for Mediator MED23 in Ras-active lung cancer. | Proc Natl Acad Sci U S A | 2012 Oct 9 | Yang X | doi: 10.1073/pnas.1204311109 |
| 21127395 | Increased expression of annexin A1 is correlated with K-ras mutation in colorectal cancer. | Tohoku J Exp Med | 2010 Dec | Su N | - |
| 23284732 | Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. | PLoS One | 2012 | Kriegl L | doi: 10.1371/journal.pone.0051654 |
| 23027075 | KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. | Br J Surg | 2012 Nov | Stremitzer S | doi: 10.1002/bjs.8909. |
| 21036740 | Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc. | Anticancer Res | 2010 Oct | Fukazawa T | - |
| 25950441 | Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer. | PLoS One | 2015 May 7 | Li Z | doi: 10.1371/journal.pone.0101019 |
| 23090619 | Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. | Cancer Chemother Pharmacol | 2013 Jan | Chen J | doi: 10.1007/s00280-012-2005-9 |
| 18049799 | The association between selected risk factors for pancreatic cancer and the expression of p53 and K-ras codon 12 mutations. | Int J Gastrointest Cancer | 2006 | Fryzek JP | - |
| 17534846 | Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. | J Pathol | 2007 Jul | Sakamoto H | - |
| 22972628 | KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. | Cancer | 2013 Feb 15 | Mao C | doi: 10.1002/cncr.27804 |
| 24629489 | KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance. | Pathol Res Pract | 2014 May | Miglio U | doi: 10.1016/j.prp.2014.01.011 |
| 27184911 | Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. | Pathol Res Pract | 2016 Jul | Krajnovic M | doi: 10.1016/j.prp.2016.02.018 |
| 15221969 | Peptide nucleic acid clamp PCR: a novel K-ras mutation detection assay for colorectal cancer micrometastases in lymph nodes. | Int J Cancer | 2004 Sep 1 | Taback B | - |
| 22753589 | Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. | Clin Cancer Res | 2012 Sep 1 | Imamura Y | doi: 10.1158/1078-0432.CCR-11-3210 |
| 23645765 | KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing. | Anticancer Res | 2013 May | Akiyoshi K | - |
| 23355875 | Detection of low-abundance KRAS mutations in colorectal cancer using microfluidic capillary electrophoresis-based restriction fragment length polymorphism method with optimized assay conditions. | PLoS One | 2013 | Zhang H | doi: 10.1371/journal.pone.0054510 |
| 26121270 | High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. | PLoS One | 2015 Jun 29 | Sorbye H | doi: 10.1371/journal.pone.0131046 |
| 26262587 | Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. | Pancreas | 2016 Feb | Lee S | doi: 10.1097/MPA.0000000000000379. |
| 21510309 | Long-term follow-up of chronic pancreatitis patients with K-ras mutation in the pancreatic juice. | Hepatogastroenterology | 2011 Jan-Feb | Kamisawa T | - |
| 19884549 | KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. | J Clin Oncol | 2009 Dec 10 | Richman SD | doi: 10.1200/JCO.2009.22.4295 |
| 19921572 | [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients]. | Zhonghua Wei Chang Wai Ke Za Zhi | 2009 Nov | Pu XX | - |
| 22865324 | Study of KRAS new predictive marker in a clinical laboratory. | Clin Transl Oncol | 2012 Dec | Bando I | doi: 10.1007/s12094-012-0886-z |
| 22876814 | Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. | BMC Cancer | 2012 Aug 9 | Kim MJ | doi: 10.1186/1471-2407-12-347. |
| 23608713 | Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. | Lung Cancer | 2013 Jul | Meng D | doi: 10.1016/j.lungcan.2013.03.019 |
| 23324583 | Duplex reverse-hybridization assay for the simultaneous detection of KRAS/BRAF mutations in FFPE-extracted genomic DNA from colorectal cancer specimens. | Dis Markers | 2013 | Buxhofer-Ausch V | doi: 10.3233/DMA-120960. |
| 21720997 | Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. | Cancer | 2012 Feb 1 | Kim HR | doi: 10.1002/cncr.26311 |
| 27179269 | Concordance of KRAS mutation status between luminal and peripheral regions of primary colorectal cancer. A laser-capture microdissection-based study. | Pol J Pathol | 2016 Mar | Lewandowska M | - |
| 24040001 | Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-γ. | PLoS One | 2013 Sep 6 | Petanidis S | doi: 10.1371/journal.pone.0073616 |
| 21441955 | Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. | Oncogene | 2011 Aug 25 | Zhang JS | doi: 10.1038/onc.2011.90 |
| 26616508 | Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. | Future Oncol | 2016 Jan | Abdel-Rahman O | doi: 10.2217/fon.15.226 |
| 23224736 | Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. | Clin Cancer Res | 2013 Feb 15 | McCleland ML | doi: 10.1158/1078-0432.CCR-12-2638 |
| 20563851 | KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. | Mol Biol Rep | 2011 Feb | Herreros-Villanueva M | doi: 10.1007/s11033-010-0232-x |
| 18386236 | Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients. | Turk J Gastroenterol | 2008 Mar | Akkiprik M | - |
| 25628445 | Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. | Ann Oncol | 2015 Apr | Morelli MP | doi: 10.1093/annonc/mdv005 |
| 17596643 | Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer. | J Korean Med Sci | 2007 Jun | Na II | - |
| 12093899 | Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. | Proc Natl Acad Sci U S A | 2002 Jul 9 | Smith G | - |
| 25401377 | Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles. | Pancreas | 2015 Mar | Zeng L | doi: 10.1097/MPA.0000000000000241. |
| 21497370 | EGFR and KRAS mutations in metastatic lung adenocarcinomas. | Hum Pathol | 2011 Oct | Munfus-McCray D | doi: 10.1016/j.humpath.2010.12.011 |
| 25742883 | High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients. | Mol Cancer | 2015 Feb 14 | Ilm K | doi: 10.1186/s12943-015-0316-2. |
| 22791568 | Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients. | Tumour Biol | 2012 Dec | Perez-Ruiz E | doi: 10.1007/s13277-012-0442-z |
| 22043994 | Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? | Anticancer Agents Med Chem | 2012 Feb | Yokota T | - |
| 15037631 | p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor. | J Biol Chem | 2004 May 21 | Qi X | - |
| 24893629 | A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. | Clin Cancer Res | 2014 Aug 1 | Vasan N | doi: 10.1158/1078-0432.CCR-13-1762 |
| 26649302 | Black Rice Anthocyanins Suppress Metastasis of Breast Cancer Cells by Targeting RAS/RAF/MAPK Pathway. | Biomed Res Int | 2015 | Chen XY | doi: 10.1155/2015/414250 |
| 23392229 | Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. | J Thorac Oncol | 2013 Apr | Yip PY | doi: 10.1097/JTO.0b013e318283558e. |
| 26970738 | Copy number of the Adenomatous Polyposis Coli gene is not always neutral in sporadic colorectal cancers with loss of heterozygosity for the gene. | BMC Cancer | 2016 Mar 12 | Zauber P | doi: 10.1186/s12885-016-2243-z. |
| 24139827 | Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. | Clin Lung Cancer | 2014 Jan | Metro G | doi: 10.1016/j.cllc.2013.08.002 |
| 22635024 | Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer. | Int J Gynecol Cancer | 2012 Jun | Ikeda Y | doi: 10.1097/IGC.0b013e31824c6ea6. |
| 18199160 | Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. | Pathol Int | 2008 Feb | Lee S | doi: 10.1111/j.1440-1827.2007.02197.x. |
| 26684803 | KRAS mutations in pancreatic circulating tumor cells: a pilot study. | Tumour Biol | 2016 Jun | Kulemann B | doi: 10.1007/s13277-015-4589-2 |
| 26432508 | Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. | Clin Lung Cancer | 2016 Jan | Goldman JW | doi: 10.1016/j.cllc.2015.08.003 |
| 23302304 | [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system]. | Zhonghua Bing Li Xue Za Zhi | 2012 Oct | Gao J | doi: 10.3760/cma.j.issn.0529-5807.2012.10.002. |
| 18202412 | KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | J Clin Oncol | 2008 Jan 20 | Lièvre A | doi: 10.1200/JCO.2007.12.5906. |
| 23098991 | MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF. | Cancer Genet | 2012 Nov | Mosakhani N | doi: 10.1016/j.cancergen.2012.08.003 |
| 24205021 | Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review. | PLoS One | 2013 Oct 21 | Rui YY | doi: 10.1371/journal.pone.0077901 |
| 24687927 | KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). | Clin Cancer Res | 2014 Jun 1 | Yoon HH | doi: 10.1158/1078-0432.CCR-13-3140 |
| 16112461 | Mutant KRAS, chromosomal instability and prognosis in colorectal cancer. | Biochim Biophys Acta | 2005 Nov 25 | Castagnola P | - |
| 20652953 | The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer. | Cancer | 2010 Nov 1 | El-Serafi MM | doi: 10.1002/cncr.25417. |
| 22938585 | High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. | Arch Pathol Lab Med | 2012 Sep | Ney JT | doi: 10.5858/arpa.2011-0176-OA. |
| 24651628 | The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer. | Int J Gynecol Cancer | 2014 May | Meyer LA | doi: 10.1097/IGC.0000000000000118. |
| 23965232 | TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. | Exp Mol Pathol | 2013 Oct | Rechsteiner M | doi: 10.1016/j.yexmp.2013.08.004 |
| 14513361 | Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. | Hum Genet | 2003 Dec | Kim IJ | - |
| 26820797 | Pre-clinical use of isogenic cell lines and tumours invitro and invivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent. | Eur J Cancer | 2016 Mar | Haagensen EJ | doi: 10.1016/j.ejca.2015.12.012 |
| 23456389 | Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma. | Ann Surg Oncol | 2013 Jul | Duldulao MP | doi: 10.1245/s10434-013-2910-0 |
| 21508389 | Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. | Anticancer Res | 2011 Apr | De Bruijn MT | - |
| 20681447 | [K-RAS gene mutations in patients with non-small cell lung cancer]. | Zhongguo Fei Ai Za Zhi | 2010 Jun | Zhang Y | doi: 10.3779/j.issn.1009-3419.2010.06.007. |
| 26220150 | Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. | Cancer Treat Rev | 2015 Sep | Hecht JR | doi: 10.1016/j.ctrv.2015.05.008 |
| 26281864 | Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer. | J Clin Pathol | 2016 Mar | Kleist B | doi: 10.1136/jclinpath-2015-202903 |
| 23526092 | Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians. | Tumour Biol | 2013 Jun | Malhotra P | doi: 10.1007/s13277-013-0734-y |
| 26525741 | High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment. | BMC Cancer | 2015 Nov 2 | Deng Y | doi: 10.1186/s12885-015-1840-6. |
| 25823645 | Eprobe-mediated screening system for somatic mutations in the KRAS locus. | Oncol Rep | 2015 Jun | Atsumi J | doi: 10.3892/or.2015.3883 |
| 25491172 | RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. | Cancer | 2015 Apr 15 | Yaeger R | doi: 10.1002/cncr.29196 |
| 26927447 | KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review. | Med Oncol | 2016 Apr | Zhou L | doi: 10.1007/s12032-016-0745-9 |
| 26771140 | CXCR2 signaling regulates KRAS(G12D)-induced autocrine growth of pancreatic cancer. | Oncotarget | 2016 Feb 9 | Purohit A | doi: 10.18632/oncotarget.6906. |
| 17184525 | High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. | BMC Cancer | 2006 Dec 21 | Krypuy M | - |
| 21155011 | Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer. | World J Gastroenterol | 2010 Dec 14 | Li FH | - |
| 23199549 | Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis. | J Surg Res | 2013 Mar | Shetty S | doi: 10.1016/j.jss.2012.10.053 |
| 21699410 | Comparison of KRAS mutation tests in colorectal cancer patients. | Genet Test Mol Biomarkers | 2011 Nov | Hancer VS | doi: 10.1089/gtmb.2011.0027 |
| 24681874 | KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. | Pancreas | 2014 May | Sinn BV | doi: 10.1097/MPA.0000000000000077. |
| 20049979 | KRAS mutation analysis on cytological specimens of metastatic colo-rectal cancer. | Diagn Cytopathol | 2010 Dec | Troncone G | doi: 10.1002/dc.21302. |
| 22662244 | The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. | PLoS One | 2012 | Pilarski R | doi: 10.1371/journal.pone.0037891 |
| 23514584 | Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. | Acta Oncol | 2013 Jun | Spindler KL | doi: 10.3109/0284186X.2013.776175 |
| 17671710 | Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. | Oncol Rep | 2007 Sep | Sasaki H | - |
| 22735045 | [Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment]. | Bull Cancer | 2012 Jul-Aug | Bibeau F | doi: 10.1684/bdc.2012.1612. |
| 26747707 | Transcriptional Regulation of miR-31 by Oncogenic KRAS Mediates Metastatic Phenotypes by Repressing RASA1. | Mol Cancer Res | 2016 Mar | Kent OA | doi: 10.1158/1541-7786.MCR-15-0456 |
| 23473612 | The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011. | Eur J Cancer | 2013 Jun | Lievre A | doi: 10.1016/j.ejca.2013.02.016 |
| 21862683 | Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. | Mol Cancer Ther | 2011 Oct | Kim ST | doi: 10.1158/1535-7163.MCT-11-0269 |
| 26418750 | Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy. | Oncotarget | 2015 Oct 13 | Alves S | doi: 10.18632/oncotarget.5021. |
| 25302858 | Comparison of PNA clamping and direct sequencing for detecting KRAS mutations in matched tumour tissue, cell block, pleural effusion and serum from patients with malignant pleural effusion. | Respirology | 2015 Jan | Kang JY | doi: 10.1111/resp.12413 |
| 24973952 | EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study. | Med Oncol | 2014 Aug | Bircan S | doi: 10.1007/s12032-014-0087-4 |
| 22922794 | The prognostic value of KRAS mutations in patients with colorectal cancer. | Oncol Rep | 2012 Nov | Inoue Y | doi: 10.3892/or.2012.1974 |
| 21447798 | Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | Sci Signal | 2011 Mar 29 | Little AS | doi: 10.1126/scisignal.2001752. |
| 21436632 | Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations. | Pathology | 2011 Apr | Egoavil CM | doi: 10.1097/PAT.0b013e3283437613. |
| 21174225 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. | Invest New Drugs | 2012 Apr | Shitara K | doi: 10.1007/s10637-010-9615-z |
| 21555681 | KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature. | J Clin Oncol | 2011 Jul 20 | Gottschling S | doi: 10.1200/JCO.2011.34.5892 |
| 24389431 | Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression. | J Thorac Oncol | 2013 Dec | Guin S | doi: 10.1097/JTO.0000000000000007. |
| 20482381 | A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples. | Clin Chem Lab Med | 2010 Aug | Wu S | doi: 10.1515/CCLM.2010.227. |
| 23752186 | EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. | Oncogene | 2014 May 8 | Tanaka M | doi: 10.1038/onc.2013.204 |
| 25689095 | Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). | Respirology | 2015 Apr | Kumarakulasinghe NB | doi: 10.1111/resp.12490 |
| 21074889 | The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. | Lung Cancer | 2011 Jun | Camps C | doi: 10.1016/j.lungcan.2010.09.005 |
| 20871266 | A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. | J Thorac Oncol | 2010 Oct | Schuurbiers OC | doi: 10.1097/JTO.0b013e3181f0bd93. |
| 25956913 | Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. | BMC Cancer | 2015 May 9 | Mortazavi F | doi: 10.1186/s12885-015-1360-4. |
| 18577988 | Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. | Br J Cancer | 2008 Jul 8 | Cappuzzo F | doi: 10.1038/sj.bjc.6604439 |
| 19002263 | Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. | PLoS One | 2008 | Nosho K | doi: 10.1371/journal.pone.0003698 |
| 26716649 | Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy. | Oncotarget | 2016 Jan 26 | Werner K | doi: 10.18632/oncotarget.6766. |
| 26775593 | Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆. | Lung Cancer | 2016 Feb | Hames ML | doi: 10.1016/j.lungcan.2015.11.004 |
| 26648033 | Regulatory single nucleotide polymorphisms at the beginning of intron 2 of the human KRAS gene. | J Biosci | 2015 Dec | Antontseva EV | - |
| 25164765 | Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. | Genome Biol | 2014 Aug 28 | Brannon AR | doi: 10.1186/s13059-014-0454-7. |
| 21031422 | Genetic alterations of K-ras may reflect prognosis in stage III colon cancer patients below 60 years of age. | J Surg Oncol | 2011 Jan 1 | Onozato W | doi: 10.1002/jso.21710. |
| 22510757 | Phenotype and polyp landscape in serrated polyposis syndrome: a series of 100 patients from genetics clinics. | Am J Surg Pathol | 2012 Jun | Rosty C | doi: 10.1097/PAS.0b013e31824e133f. |
| 22139083 | A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. | Oncogene | 2012 Oct 18 | Ratner ES | doi: 10.1038/onc.2011.539 |
| 25666295 | FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. | Clin Colorectal Cancer | 2015 Jun | Kaczirek K | doi: 10.1016/j.clcc.2014.12.003 |
| 23435671 | KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. | J Gastroenterol | 2013 Apr | Boeck S | doi: 10.1007/s00535-013-0767-4 |
| 19745602 | LIN28B confers radio-resistance through the posttranscriptional control of KRAS. | Exp Mol Med | 2009 Dec 31 | Jeong SH | doi: 10.3858/emm.2009.41.12.097. |
| 28179313 | Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps. | Anticancer Res | 2017 Feb | Galanopoulos M | - |
| 24956168 | Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour. | PLoS One | 2014 Jun 23 | Sherwood JL | doi: 10.1371/journal.pone.0100566 |
| 25577224 | Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis. | J Cancer Res Clin Oncol | 2015 Aug | Ying M | doi: 10.1007/s00432-015-1910-9 |
| 22000810 | The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. | Clin Colorectal Cancer | 2011 Dec | Mitchell EP | doi: 10.1016/j.clcc.2011.06.004 |
| 25023699 | Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs. | Oncogene | 2015 May 14 | Saqcena M | doi: 10.1038/onc.2014.207 |
| 22526587 | KRAS mutation and NF-κB activation indicates tolerance of chemotherapy and poor prognosis in colorectal cancer. | Dig Dis Sci | 2012 Sep | Lin G | doi: 10.1007/s10620-012-2172-x |
| 25561800 | Comparative study of mutations in SNP loci of K-RAS, hMLH1 and hMSH2 genes in neoplastic intestinal polyps and colorectal cancer. | World J Gastroenterol | 2014 Dec 28 | Yan ZH | doi: 10.3748/wjg.v20.i48.18338. |
| 23341890 | Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer. | PLoS One | 2013 | Li Y | doi: 10.1371/journal.pone.0052093 |
| 19096301 | Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). | J Thorac Oncol | 2009 Jan | Lim EH | doi: 10.1097/JTO.0b013e3181913e28. |
| 24696490 | Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity. | J Virol | 2014 Jun | Cuddington BP | doi: 10.1128/JVI.00849-14 |
| 22638623 | Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer. | Int J Clin Oncol | 2013 Aug | Soeda H | doi: 10.1007/s10147-012-0422-8 |
| 22929917 | Association of folate intake, dietary habits, smoking and COX-2 promotor -765G>C polymorphism with K-ras mutation in patients with colorectal cancer. | J Egypt Natl Canc Inst | 2012 Sep | Kamal MM | doi: 10.1016/j.jnci.2012.05.002 |
| 18265644 | The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients. | Hepatogastroenterology | 2007 Dec | Wang JY | - |
| 19661383 | Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. | Science | 2009 Sep 18 | Yun J | doi: 10.1126/science.1174229 |
| 12972432 | Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression. | J Biol Chem | 2003 Nov 21 | Klampfer L | - |
| 26498594 | Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. | BMC Cancer | 2015 Oct 24 | Earl J | doi: 10.1186/s12885-015-1779-7. |
| 24024839 | Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. | N Engl J Med | 2013 Sep 12 | Douillard JY | doi: 10.1056/NEJMoa1305275. |
| 21910869 | Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. | Radiat Oncol | 2011 Sep 12 | Davies JM | doi: 10.1186/1748-717X-6-114. |
| 21390154 | Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. | World J Gastroenterol | 2011 Feb 14 | Shen H | doi: 10.3748/wjg.v17.i6.809. |
| 23524403 | KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. | J Thorac Oncol | 2013 May | Martin P | doi: 10.1097/JTO.0b013e318283d958. |
| 23625655 | Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? | Tumour Biol | 2013 Aug | Selcukbiricik F | doi: 10.1007/s13277-013-0763-6 |
| 26316738 | A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD. | Int J Chron Obstruct Pulmon Dis | 2015 Aug 17 | Hu H | doi: 10.2147/COPD.S83596 |
| 23157824 | [KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese]. | Zhonghua Bing Li Xue Za Zhi | 2012 Sep | Zhu XL | doi: 10.3760/cma.j.issn.0529-5807.2012.09.003. |
| 19574674 | Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. | Indian J Cancer | 2009 Jul-Sep | Sameer AS | doi: 10.4103/0019-509X.52956. |
| 25499080 | Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. | Cancer Lett | 2015 Feb 28 | Yang L | doi: 10.1016/j.canlet.2014.12.003 |
| 25663768 | MiR-21/RASA1 axis affects malignancy of colon cancer cells via RAS pathways. | World J Gastroenterol | 2015 Feb 7 | Gong B | doi: 10.3748/wjg.v21.i5.1488. |
| 21169348 | Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer. | Jpn J Clin Oncol | 2011 Feb | Doi T | doi: 10.1093/jjco/hyq229 |
| 22964644 | Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. | Oncogene | 2013 Aug 22 | Sunaga N | doi: 10.1038/onc.2012.402 |
| 21239505 | KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. | Clin Cancer Res | 2011 Mar 1 | Tie J | doi: 10.1158/1078-0432.CCR-10-1720 |
| 19637313 | TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors. | Int J Cancer | 2009 Nov 1 | Oikonomou E | doi: 10.1002/ijc.24613. |
| 23755178 | Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. | PLoS One | 2013 Jun 3 | Huang CJ | doi: 10.1371/journal.pone.0065117 |
| 17549340 | Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing. | Oncol Rep | 2007 Jul | Chong IW | - |
| 21985784 | Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. | J Clin Invest | 2011 Nov | Ebi H | doi: 10.1172/JCI57909 |
| 24011934 | Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. | Eur J Cancer | 2013 Dec | Sheppard KE | doi: 10.1016/j.ejca.2013.08.007 |
| 23238036 | The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. | Lung Cancer | 2013 Mar | Nygaard AD | doi: 10.1016/j.lungcan.2012.11.016 |
| 22672749 | KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials. | Int J Radiat Oncol Biol Phys | 2013 Jan 1 | Kim SY | doi: 10.1016/j.ijrobp.2012.03.048 |
| 26610798 | KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. | Mol Diagn Ther | 2016 Feb | Dadduzio V | doi: 10.1007/s40291-015-0178-8. |
| 22386733 | Absence of evidence for epidermal growth factor receptor and human homolog of the Kirsten rat sarcoma-2 virus oncogene mutations in breast cancer. | Cancer Epidemiol | 2012 Aug | Lv N | doi: 10.1016/j.canep.2012.01.004 |
| 23838952 | Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer. | Dig Surg | 2013 | Kazmi HR | doi: 10.1159/000353133 |
| 24890702 | Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis. | Cancer Med | 2014 Oct | Langevin SM | doi: 10.1002/cam4.279 |
| 24219000 | K-Ras, intestinal homeostasis and colon cancer. | Curr Clin Pharmacol | 2015 | Goel S | - |
| 12826308 | K-ras mutations in lung carcinomas from nonsmoking women exposed to unvented coal smoke in China. | Lung Cancer | 2003 Jul | Keohavong P | - |
| 25197873 | KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. | Am Surg | 2014 Sep | Tignanelli CJ | - |
| 21435948 | A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. | Lancet Oncol | 2011 Apr | Paranjape T | doi: 10.1016/S1470-2045(11)70044-4 |
| 22044911 | K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer. | Pancreas | 2012 Mar | Dabritz J | doi: 10.1097/MPA.0b013e3182289118. |
| 26740498 | Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. | J Int Med Res | 2016 Feb | Zhou H | doi: 10.1177/0300060515607383 |
| 24594201 | Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. | Genet Res (Camb) | 2014 | Carneiro JG | doi: 10.1017/S0016672314000032 |
| 24582914 | RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. | Eur J Cancer | 2014 May | Sclafani F | doi: 10.1016/j.ejca.2014.02.002 |
| 21252116 | IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2. | Cancer Res | 2011 Mar 15 | Mongroo PS | doi: 10.1158/0008-5472.CAN-10-3295 |
| 25699356 | Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer. | Hepatogastroenterology | 2014 Nov-Dec | Koike J | - |
| 24947927 | Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. | Clin Cancer Res | 2014 Aug 15 | Zimmer L | doi: 10.1158/1078-0432.CCR-14-0341 |
| 24122611 | EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. | Histol Histopathol | 2014 Apr | Martin V | doi: 10.14670/HH-29.10.513 |
| 26636714 | Combined Delivery of Let-7b MicroRNA and Paclitaxel via Biodegradable Nanoassemblies for the Treatment of KRAS Mutant Cancer. | Mol Pharm | 2016 Feb 1 | Dai X | doi: 10.1021/acs.molpharmaceut.5b00756 |
| 23155138 | KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. | Cancer Epidemiol Biomarkers Prev | 2013 Jan | Webster J | doi: 10.1158/1055-9965.EPI-12-0545 |
| 20575464 | Comparison of two different screening methods for the KRAS mutation in colorectal cancer. | Clin Lab | 2010 | Er TK | - |
| 24440976 | Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer. | Cancer Biomark | 2013 | Kang M | doi: 10.3233/CBM-130366. |
| 27466537 | Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer. | Anticancer Res | 2016 Aug | Ploquin A | - |
| 22489692 | Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. | Neoplasma | 2012 | Rako I | doi: 10.4149/neo_2012_049. |
| 15514939 | A novel high-specificity approach for colorectal neoplasia: Detection of K-ras2 oncogene mutation in normal mucosa. | Int J Cancer | 2005 Mar 1 | Yamada S | - |
| 17998284 | KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. | Ann Oncol | 2008 Mar | De Roock W | - |
| 19936839 | KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. | Ann Surg Oncol | 2010 Apr | Siddiqui AD | doi: 10.1245/s10434-009-0811-z |
| 19813061 | KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. | Ann Surg Oncol | 2010 Feb | Nash GM | doi: 10.1245/s10434-009-0713-0 |
| 25929517 | Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. | BMC Cancer | 2015 May 1 | Li W | doi: 10.1186/s12885-015-1345-3. |
| 21742770 | STK33 kinase activity is nonessential in KRAS-dependent cancer cells. | Cancer Res | 2011 Sep 1 | Babij C | doi: 10.1158/0008-5472.CAN-11-0778 |
| 17629419 | K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. | Pathol Res Pract | 2007 | Poehlmann A | - |
| 22535956 | Novel AKT1-GLI3-VMP1 pathway mediates KRAS oncogene-induced autophagy in cancer cells. | J Biol Chem | 2012 Jul 20 | Lo Ré AE | doi: 10.1074/jbc.M112.370809 |
| 26325669 | Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. | Oncotarget | 2015 Sep 22 | Formisano L | doi: 10.18632/oncotarget.4636. |
| 19281127 | [K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer]. | Vojnosanit Pregl | 2009 Feb | Cvetkovic G | - |
| 21855038 | An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. | Clin Colorectal Cancer | 2011 Sep | Cohn AL | doi: 10.1016/j.clcc.2011.03.022 |
| 26384309 | Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. | Oncotarget | 2015 Oct 13 | Vincenzi B | doi: 10.18632/oncotarget.5231. |
| 26429158 | KRAS gene mutations - prognostic factor in colorectal cancer? | Rom J Morphol Embryol | 2015 | Dobre M | - |
| 26028668 | High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. | Oncotarget | 2015 May 10 | Thomas A | - |
| 17704924 | Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients. | Int J Colorectal Dis | 2008 Jan | Jeon CH | - |
| 25050586 | KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy. | Oncol Rep | 2014 Oct | Yamane LS | doi: 10.3892/or.2014.3338 |
| 26925650 | Mutation Analysis of KRAS and BRAF Genes in Metastatic Colorectal Cancer: a First Large Scale Study from Iran. | Asian Pac J Cancer Prev | 2016 | Koochak A | - |
| 26028111 | KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials. | Asian Pac J Cancer Prev | 2015 | Ying M | - |
| 22016105 | Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer. | Virchows Arch | 2011 Nov | Farber L | doi: 10.1007/s00428-011-1158-y |
| 21947301 | EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. | J Clin Pathol | 2011 Oct | Thunnissen E | doi: 10.1136/jclinpath-2011-200163. |
| 22113502 | Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. | Oncotarget | 2011 Nov | Qiu W | - |
| 24172884 | Androgen receptor decreases CMYC and KRAS expression by upregulating let-7a expression in ER-, PR-, AR+ breast cancer. | Int J Oncol | 2014 Jan | Lyu S | doi: 10.3892/ijo.2013.2151 |
| 27793187 | A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS. | Chin J Cancer | 2016 Oct 28 | Pang X | - |
| 26802155 | Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. | Ann Oncol | 2016 Apr | Carter CA | doi: 10.1093/annonc/mdw008 |
| 19671843 | Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. | Clin Cancer Res | 2009 Aug 15 | Jackman DM | doi: 10.1158/1078-0432.CCR-09-0888 |
| 26544625 | Oncogenic Ras suppresses ING4-TDG-Fas axis to promote apoptosis resistance. | Oncotarget | 2015 Dec 8 | Sun J | doi: 10.18632/oncotarget.6015. |
| 21847063 | A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. | J Thorac Oncol | 2011 Aug | Riely GJ | doi: 10.1097/JTO.0b013e318223c099. |
| 16969076 | Recurrent KRAS codon 146 mutations in human colorectal cancer. | Cancer Biol Ther | 2006 Aug | Edkins S | - |
| 27356691 | Oncogenic Activation of Fibroblast Growth Factor Receptor-3 and RAS Genes as Non-Overlapping Mutual Exclusive Events in Urinary Bladder Cancer. | Asian Pac J Cancer Prev | 2016 | Pandith AA | - |
| 19847166 | Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. | Nature | 2009 Nov 5 | Barbie DA | doi: 10.1038/nature08460 |
| 26077004 | Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population. | Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub | 2015 Sep | Uvirova M | doi: 10.5507/bp.2015.029 |
| 27509933 | Evaluation of KRAS Gene Mutations in Metastatic Colorectal Cancer Patients in Kermanshah Province. | Asian Pac J Cancer Prev | 2016 | Amirifard N | - |
| 24055406 | Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. | Respir Med | 2013 Nov | Hosgood HD 3rd | doi: 10.1016/j.rmed.2013.08.018 |
| 18676835 | Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer. | Cancer Res | 2008 Aug 1 | Macias-Perez I | doi: 10.1158/0008-5472.CAN-08-1395. |
| 19603018 | KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. | Br J Cancer | 2009 Aug 18 | Loupakis F | doi: 10.1038/sj.bjc.6605177 |
| 17172815 | Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. | Cancer Biol Ther | 2006 Nov | Zhang Z | - |
| 20372787 | KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. | Int J Oncol | 2010 May | Licar A | - |
| 22383492 | Oncogenic KRAS regulates BMP4 expression in colon cancer cell lines. | Am J Physiol Gastrointest Liver Physiol | 2012 May 15 | Duerr EM | doi: 10.1152/ajpgi.00047.2011 |
| 23511561 | KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. | Br J Cancer | 2013 Apr 16 | van Grieken NC | doi: 10.1038/bjc.2013.109 |
| 24798549 | Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. | Oncotarget | 2014 May 15 | Maitra R | - |
| 26829579 | Detection of KRAS mutations using double-stranded toehold-exchange probes. | Biosens Bioelectron | 2016 Jun 15 | Wu Z | doi: 10.1016/j.bios.2016.01.055 |
| 17697521 | No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. | J Int Med Res | 2007 Jul-Aug | Kimura K | - |
| 23864308 | KRAS mutations and rectal cancer response to chemoradiation: are we closer to personalization of therapy? | Ann Surg Oncol | 2013 Oct | Krishnan S | doi: 10.1245/s10434-013-3107-2 |
| 19238210 | Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. | PLoS One | 2009 | Gandhi J | doi: 10.1371/journal.pone.0004576 |
| 22770374 | Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. | Lung Cancer | 2012 Oct | Metro G | doi: 10.1016/j.lungcan.2012.06.005 |
| 23817662 | Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients. | Oncol Rep | 2013 Sep | Lewandowska MA | doi: 10.3892/or.2013.2579 |
| 22701724 | Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. | PLoS One | 2012 | Tanic M | doi: 10.1371/journal.pone.0038847 |
| 19018267 | KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. | Br J Cancer | 2008 Dec 16 | Nakayama N | doi: 10.1038/sj.bjc.6604783 |
| 24398677 | Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. | J Biol Chem | 2014 Feb 14 | Kahlert C | doi: 10.1074/jbc.C113.532267 |
| 24505265 | Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients. | PLoS One | 2014 Feb 4 | Lin YL | doi: 10.1371/journal.pone.0086789 |
| 23510802 | KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. | Eur J Cancer | 2013 Jul | Smith JC | doi: 10.1016/j.ejca.2013.02.023 |
| 22341439 | TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. | Cell | 2012 Feb 17 | Singh A | doi: 10.1016/j.cell.2011.12.033. |
| 27008036 | Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer. | PLoS One | 2016 Mar 23 | Saber A | doi: 10.1371/journal.pone.0152317 |
| 21129603 | Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. | Cancer Treat Rev | 2010 Nov | Sartore-Bianchi A | doi: 10.1016/S0305-7372(10)70012-8. |
| 25911860 | K-Ras mutation and prognosis of colorectal cancer: a meta-analysis. | Hepatogastroenterology | 2015 Jan-Feb | Rui Y | - |
| 17192038 | Detection of a K-ras mutation in urine of patients with colorectal cancer. | Cancer Biomark | 2005 | Su YH | - |
| 23174662 | KRAS above and beyond - EGFR in pancreatic cancer. | Oncotarget | 2012 Nov | Siveke JT | - |
| 20592359 | Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. | Anticancer Res | 2010 May | Benesova L | - |
| 19179548 | The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. | Ann Oncol | 2009 May | Garm Spindler KL | doi: 10.1093/annonc/mdn712 |
| 23473635 | KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. | Surg Oncol | 2013 Jun | Clancy C | doi: 10.1016/j.suronc.2013.02.001 |
| 24659028 | Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. | Int J Cancer | 2014 Nov 1 | Spindler KL | doi: 10.1002/ijc.28863 |
| 19164213 | Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. | J Clin Oncol | 2009 Mar 1 | Bibeau F | doi: 10.1200/JCO.2008.18.0463 |
| 23280667 | Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. | Int J Cancer | 2013 Jul | Basu Roy UK | doi: 10.1002/ijc.28001 |
| 21271222 | KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. | Oncol Rep | 2011 Apr | Kurtze I | doi: 10.3892/or.2011.1160 |
| 21962894 | Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. | Cancer Genet | 2011 Aug | Pinto P | doi: 10.1016/j.cancergen.2011.07.003. |
| 26209642 | Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. | Ann Oncol | 2015 Oct | Rulli E | doi: 10.1093/annonc/mdv318 |
| 23370967 | Ras inhibition enhances autophagy, which partially protects cells from death. | Oncotarget | 2013 Jan | Schmukler E | - |
| 24463346 | The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. | Curr Opin Oncol | 2014 Mar | Timar J | doi: 10.1097/CCO.0000000000000051. |
| 17449174 | Origin and prognostic value of circulating KRAS mutations in lung cancer patients. | Cancer Lett | 2007 Sep 8 | Gautschi O | - |
| 24954536 | KRAS and YAP1 converge to regulate EMT and tumor survival. | Cell | 2014 Jul 3 | Shao DD | doi: 10.1016/j.cell.2014.06.004 |
| 15112354 | Detection of K-ras point mutation and telomerase activity during endoscopic retrograde cholangiopancreatography in diagnosis of pancreatic cancer. | World J Gastroenterol | 2004 May 1 | Zhou GX | - |
| 23033302 | KRAS and BRAF mutations in Serbian patients with colorectal cancer. | J BUON | 2012 Jul-Sep | Jakovljevic K | - |
| 23865079 | Loss of RASSF1A expression in colorectal cancer and its association with K-ras status. | Biomed Res Int | 2013 | Cao D | doi: 10.1155/2013/976765 |
| 16158056 | Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer. | Oncogene | 2006 Jan 5 | Seiden-Long IM | - |
| 26515332 | KRAS polymorphisms are associated with survival of CRC in Chinese population. | Tumour Biol | 2016 Apr | Dai Q | doi: 10.1007/s13277-015-4314-1 |
| 21737635 | Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models. | Anticancer Res | 2011 Jun | Prewett M | - |
| 23640097 | The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer. | Mol Biol Rep | 2013 Jun | Ouerhani S | doi: 10.1007/s11033-013-2512-8 |
| 22446022 | Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. | Eur J Cancer | 2012 Jul | Bokemeyer C | doi: 10.1016/j.ejca.2012.02.057 |
| 22864777 | Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer. | Pol J Pathol | 2012 Jun | Tai CJ | - |
| 20718705 | KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence. | Curr Cancer Drug Targets | 2010 Dec | Timar J | - |
| 24952473 | Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. | Oncotarget | 2014 Jul 15 | Brunelli L | - |
| 19056857 | High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. | Oncologist | 2008 Dec | Santini D | doi: 10.1634/theoncologist.2008-0181 |
| 23015072 | KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. | J Cancer Res Clin Oncol | 2013 Feb | Messner I | doi: 10.1007/s00432-012-1319-7 |
| 20959826 | KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis. | Br J Cancer | 2010 Nov 9 | Deschoolmeester V | doi: 10.1038/sj.bjc.6605959 |
| 25167228 | KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. | Br J Cancer | 2014 Oct 28 | Hamidi H | doi: 10.1038/bjc.2014.475 |
| 21994416 | A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. | Clin Cancer Res | 2011 Dec 15 | Smits KM | doi: 10.1158/1078-0432.CCR-11-0990 |
| 22579930 | Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. | Clin Chim Acta | 2012 Oct 9 | Hsieh LL | doi: 10.1016/j.cca.2012.04.029 |
| 21876563 | Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis. | Am J Gastroenterol | 2011 Dec | Wang X | doi: 10.1038/ajg.2011.281 |
| 19545448 | A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. | BMC Cancer | 2009 Jun 23 | Mita H | doi: 10.1186/1471-2407-9-198. |
| 26026309 | Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13. | Genomics | 2015 Aug | Kawamata H | doi: 10.1016/j.ygeno.2015.05.007 |
| 23790176 | Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients. | Neoplasma | 2013 | Chen MC | doi: 10.4149/neo_2013_073. |
| 23026641 | Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. | Lung Cancer | 2012 Dec | Yamaguchi F | doi: 10.1016/j.lungcan.2012.08.014 |
| 20583472 | K-ras expression--marker of dysplasia and cancer. | Roum Arch Microbiol Immunol | 2009 Oct-Dec | Bleotu C | - |
| 27183870 | Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis. | World J Surg Oncol | 2016 May 16 | Tao LY | doi: 10.1186/s12957-016-0888-3. |
| 22675430 | KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. | PLoS One | 2012 | Garrido-Laguna I | doi: 10.1371/journal.pone.0038033 |
| 24282149 | Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. | Hum Mutat | 2014 Feb | Crowley EH | doi: 10.1002/humu.22487 |
| 22498935 | Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis. | Int J Gynecol Pathol | 2012 May | Peterson LM | doi: 10.1097/PGP.0b013e318231fc51. |
| 23022742 | Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer. | Exp Mol Pathol | 2013 Feb | Alsdorf WH | doi: 10.1016/j.yexmp.2012.09.016 |
| 25884297 | Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. | BMC Cancer | 2015 Mar 14 | Birgisson H | doi: 10.1186/s12885-015-1144-x. |
| 21468700 | Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. | J Cancer Res Clin Oncol | 2011 Jul | Schimanski CC | doi: 10.1007/s00432-011-0980-6 |
| 24642668 | Analysis of KRAS mutations in cases of metastatic colorectal cancer at a single institution in Tochigi, Japan. | Pathobiology | 2014 | Saito N | doi: 10.1159/000357812 |
| 26744320 | Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation. | Oncotarget | 2016 Jan 19 | Le Rolle AF | doi: 10.18632/oncotarget.6818. |
| 23090042 | KRAS mutations are associated with specific morphologic features in colon cancer. | J Clin Gastroenterol | 2013 Jul | Gunal A | doi: 10.1097/MCG.0b013e3182703030. |
| 19549774 | Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. | Clin Cancer Res | 2009 Jul 1 | Yen LC | doi: 10.1158/1078-0432.CCR-08-3179 |
| 25359494 | Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. | FASEB J | 2015 Feb | Alamo P | doi: 10.1096/fj.14-262303 |
| 24720724 | KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. | BMC Gastroenterol | 2014 Apr 10 | Gil Ferreira C | doi: 10.1186/1471-230X-14-73. |
| 26600545 | Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai. | Genet Mol Res | 2015 Nov 23 | Wang YL | doi: 10.4238/2015.November.18.49. |
| 20845292 | Genetic aberrations of the K-ras proto-oncogene in bladder cancer in Kashmiri population. | Urol J | 2010 Summer | Nanda MS | - |
| 24906690 | Relationships between KRAS mutation status and baseline radiographic distribution of disease in patients with stage IV colorectal cancer. | Abdom Imaging | 2014 Dec | Rosenthal MH | doi: 10.1007/s00261-014-0165-2. |
| 26887348 | The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis. | BMC Cancer | 2016 Feb 18 | Kim HS | doi: 10.1186/s12885-016-2141-4. |
| 25086186 | Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH. | Cancer Lett | 2014 Oct 28 | Das K | doi: 10.1016/j.canlet.2014.07.021 |
| 26799184 | Comparison of liver oncogenic potential among human RAS isoforms. | Oncotarget | 2016 Feb 9 | Chung SI | doi: 10.18632/oncotarget.6931. |
| 21109984 | Tissue sampling for mutation analysis in colorectal cancer: K-ras is homogeneously distributed throughout the tumor tissue. | Oncol Rep | 2011 Jan | Ekelund S | - |
| 26710843 | Impact of KRAS variant rs61764370 on breast cancer morbidity. | Exp Oncol | 2015 Dec | Ustinova M | - |
| 21228335 | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. | Ann Oncol | 2011 Jul | Bokemeyer C | doi: 10.1093/annonc/mdq632 |
| 15741570 | Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. | J Natl Cancer Inst | 2005 Mar 2 | Shigematsu H | - |
| 23723075 | HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS. | Mol Cancer Res | 2013 Sep | Yang MH | doi: 10.1158/1541-7786.MCR-13-0040-T |
| 23208128 | KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy. | Ann Surg Oncol | 2013 Apr | Guan JL | doi: 10.1245/s10434-012-2754-z |
| 23729275 | A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer. | Tumour Biol | 2013 Oct | Li ZH | doi: 10.1007/s13277-013-0885-x |
| 27064574 | Heterogeneity of KRAS Mutation Status in Rectal Cancer. | PLoS One | 2016 Apr 11 | Jo P | doi: 10.1371/journal.pone.0153278 |
| 26520779 | [KRAS and bronchial adenocarcinoma. Between disappointments and hopes]. | Rev Mal Respir | 2016 Feb | Guibert N | doi: 10.1016/j.rmr.2015.05.012 |
| 23874486 | Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy. | PLoS One | 2013 Jul 9 | Yu S | doi: 10.1371/journal.pone.0068022 |
| 24648348 | EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. | Cancer Res | 2014 May 15 | Wang M | doi: 10.1158/0008-5472.CAN-13-3157 |
| 25201577 | Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. | Med Oncol | 2014 Oct | Jin H | doi: 10.1007/s12032-014-0221-3 |
| 22810479 | Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis. | Dis Colon Rectum | 2012 Aug | Ren J | doi: 10.1097/DCR.0b013e318251d8d9. |
| 26842935 | Aurora kinase targeting in lung cancer reduces KRAS-induced transformation. | Mol Cancer | 2016 Feb 3 | Dos Santos EO | doi: 10.1186/s12943-016-0494-6. |
| 24935174 | Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets. | Genes Chromosomes Cancer | 2014 Nov | Qian Z | doi: 10.1002/gcc.22196 |
| 23021375 | EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. | Discov Med | 2012 Sep | Berg M | - |
| 21097396 | [Construction of let-7a expression plasmid and its inhibitory effect on k-Ras protein in A549 lung cancer cells]. | Nan Fang Yi Ke Da Xue Xue Bao | 2010 Nov | He XY | - |
| 26028026 | Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP. | Oncogene | 2016 Mar 10 | Ricoult SJ | doi: 10.1038/onc.2015.179 |
| 12032847 | K-ras mutations and RASSF1A promoter methylation in colorectal cancer. | Oncogene | 2002 May 23 | van Engeland M | - |
| 17632319 | Lifetime history of tobacco consumption and K-ras mutations in exocrine pancreatic cancer. | Pancreas | 2007 Aug | Crous-Bou M | - |
| 23455880 | KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. | J Cancer Res Clin Oncol | 2013 Jun | Modest DP | doi: 10.1007/s00432-013-1401-9 |
| 21383284 | Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. | J Clin Oncol | 2011 Apr 1 | Hutchins G | doi: 10.1200/JCO.2010.30.1366 |
| 23613396 | The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. | J BUON | 2013 Jan-Mar | Selcukbiricik F | - |
| 26275461 | Hsa-miR-1 suppresses breast cancer development by down-regulating K-ras and long non-coding RNA MALAT1. | Int J Biol Macromol | 2015 Nov | Liu R | doi: 10.1016/j.ijbiomac.2015.08.016 |
| 17130841 | Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS:gelsolin complex. | Oncogene | 2007 May 10 | Keller JW | - |
| 15923430 | Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. | Ann Oncol | 2005 May | Bazan V | - |
| 25688918 | KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer. | Br J Cancer | 2015 Feb 17 | Renaud S | doi: 10.1038/bjc.2014.499. |
| 23374602 | Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. | BMC Cancer | 2013 Feb 2 | Pentheroudakis G | doi: 10.1186/1471-2407-13-49. |
| 21150464 | Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. | J Thorac Oncol | 2011 Jan | Sasaki H | doi: 10.1097/JTO.0b013e31820594f0. |
| 24407191 | Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. | Br J Cancer | 2014 Mar 4 | Samalin E | doi: 10.1038/bjc.2013.813 |
| 24595598 | EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. | J Cancer Res Clin Oncol | 2014 May | Razis E | doi: 10.1007/s00432-014-1626-2 |
| 24244261 | Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. | PLoS One | 2013 Nov 11 | Siena S | doi: 10.1371/journal.pone.0062264 |
| 23787801 | KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. | J Thorac Oncol | 2013 Sep | Mellema WW | doi: 10.1097/JTO.0b013e318298764e. |
| 23999847 | K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011. | Int J Biol Markers | 2013 Dec 17 | Ruiz-Candelaria Y | doi: 10.5301/JBM.5000043. |
| 20842128 | Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. | Br J Cancer | 2010 Sep 28 | Bengala C | doi: 10.1038/sj.bjc.6605853 |
| 25961464 | Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. | Cell Cycle | 2015 | McVeigh TP | doi: 10.1080/15384101.2015.1041694 |
| 19881948 | BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. | Neoplasia | 2009 Nov | Oikonomou E | - |
| 16448675 | Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer. | Mutat Res | 2006 Mar 20 | Samowitz WS | - |
| 19190129 | Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. | Clin Cancer Res | 2009 Feb 15 | Kumar K | doi: 10.1158/1078-0432.CCR-08-1029 |
| 23288781 | Targeted degradation of KRAS by an engineered ubiquitin ligase suppresses pancreatic cancer cell growth in vitro and in vivo. | Mol Cancer Ther | 2013 Mar | Ma Y | doi: 10.1158/1535-7163.MCT-12-0650 |
| 20610624 | miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. | Cancer Res | 2010 Jul 15 | Yu S | doi: 10.1158/0008-5472.CAN-09-4531 |
| 25065594 | Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. | Oncogene | 2015 May 21 | Park JT | doi: 10.1038/onc.2014.223 |
| 26775732 | Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. | Crit Rev Oncol Hematol | 2016 Mar | Passiglia F | doi: 10.1016/j.critrevonc.2015.12.015 |
| 26563370 | Emerging prognostic markers related to mesenchymal characteristics of poorly differentiated breast cancers. | Tumour Biol | 2016 Apr | Scimeca M | doi: 10.1007/s13277-015-4361-7 |
| 23538866 | KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. | Am J Clin Oncol | 2015 Feb | Campos-Parra AD | doi: 10.1097/COC.0b013e318287bb23. |
| 28000889 | High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. | Oncol Rep | 2017 Feb | Fujiyoshi K | doi: 10.3892/or.2016.5323 |
| 28489996 | Cancer-Associated Mutations in Endometriosis without Cancer. | N Engl J Med | 2017 May 11 | Anglesio MS | doi: 10.1056/NEJMoa1614814. |
| 25902737 | Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancer. | Clin Exp Med | 2016 May | Nicos M | doi: 10.1007/s10238-015-0349-2 |
| 27444698 | Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. | World J Surg Oncol | 2016 Jul 22 | Schmitz KJ | doi: 10.1186/s12957-016-0946-x. |
| 28233357 | Promotion of invasion by mutant RAS is dependent on activation of the WASF3 metastasis promoter gene. | Genes Chromosomes Cancer | 2017 Jun | Teng Y | doi: 10.1002/gcc.22453 |
| 27737491 | Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. | Cancer | 2017 Feb 15 | Frankel TL | doi: 10.1002/cncr.30351 |
| 27225938 | K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis. | Med Oncol | 2016 Jul | Li T | doi: 10.1007/s12032-016-0777-1 |
| 28074351 | KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. | Med Oncol | 2017 Feb | Cicenas J | doi: 10.1007/s12032-016-0879-9 |
| 28000854 | Identification of microRNA-487b as a negative regulator of liver metastasis by regulation of KRAS in colorectal cancer. | Int J Oncol | 2017 Feb | Hata T | doi: 10.3892/ijo.2016.3813 |
| 27237100 | A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer. | Pancreatology | 2016 Jul-Aug | Yang J | doi: 10.1016/j.pan.2016.04.033 |
| 27343315 | Chromosome aberrations [dup(1q)] in endometrial cancer: Gene analysis of 54 surgical specimens in Turkey. | Taiwan J Obstet Gynecol | 2016 Jun | Sever E | doi: 10.1016/j.tjog.2016.02.012. |
| 28314302 | KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer. | Anticancer Res | 2017 Mar | Sideris M | - |
| 28006055 | Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. | JAMA Oncol | 2017 Apr 1 | Sinicrope FA | doi: 10.1001/jamaoncol.2016.5469. |
| 28208157 | Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. | Br J Cancer | 2017 Mar 28 | Jones RP | doi: 10.1038/bjc.2017.37 |
| 27999344 | EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2016 Dec 18 | Tomasini P | doi: 10.3390/ijms17122132. |
| 27451147 | SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate. | Gastroenterology | 2016 Nov | Wong CC | doi: 10.1053/j.gastro.2016.07.011 |
| 27906963 | LncRNA-RMRP Acts as an Oncogene in Lung Cancer. | PLoS One | 2016 Dec 1 | Meng Q | doi: 10.1371/journal.pone.0164845 |
| 28202657 | Deciphering the RAS/ERK pathway in vivo. | Biochem Soc Trans | 2017 Feb 8 | Dorard C | doi: 10.1042/BST20160135. |
| 27698189 | miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3. | Cancer Res | 2016 Oct 1 | Zhou Y | - |
| 28154181 | USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. | J Biol Chem | 2017 Mar 10 | Fraile JM | doi: 10.1074/jbc.M116.762757 |
| 26808395 | Clinicopathological, endoscopic, and molecular characteristics of the skirt - a new entity of lesions at the margin of laterally spreading tumors. | Endoscopy | 2016 May | Osera S | doi: 10.1055/s-0041-111565 |
| 26945839 | A Crosstalk Between K ras (Kirsten Rat Sarcoma Viral Oncogene Homologue) and Adherence Molecular Complex Leads to Disassociation of Cells-A Possible Contribution Towards Metastasis in Colorectal Cancer. | J Cell Biochem | 2016 Oct | Murtaza BN | doi: 10.1002/jcb.25531 |
| 27530493 | Epidermal growth factor receptor and v-Ki-ras2 Kirsten rat sarcoma viral oncogen homologue-specific amino acid substitutions are associated with different histopathological prognostic factors in resected non-small-cell lung cancer. | Interact Cardiovasc Thorac Surg | 2016 Dec | Seitlinger J | - |
| 28453411 | Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. | J Clin Oncol | 2017 Jun 20 | Shepherd FA | doi: 10.1200/JCO.2016.71.2893 |
| 28152508 | KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents. | Oncotarget | 2017 Mar 14 | Ischenko I | doi: 10.18632/oncotarget.14929. |
| 27753016 | Screening of KRAS Mutation in Pre- and Post-Surgery Serum of Patients Suffering from Colon Cancer by COLD-PCR HRM. | Adv Exp Med Biol | 2016 | Trujillo-Arribas E | - |
| 28099923 | Significant association between Let-7-KRAS rs712 G > T polymorphism and cancer risk in the Chinese population: a meta-analysis. | Oncotarget | 2017 Feb 21 | Du XY | doi: 10.18632/oncotarget.14672. |
| 28636636 | SensiScreenKRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations. | PLoS One | 2017 Jun 21 | Riva A | doi: 10.1371/journal.pone.0178027 |
| 28576749 | A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. | Cancer Lett | 2017 Aug 28 | Zhao X | doi: 10.1016/j.canlet.2017.05.015 |
| 28858102 | Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis. | Medicine (Baltimore) | 2017 Sep | Kwak MS | doi: 10.1097/MD.0000000000007882. |
| 28796802 | The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. | PLoS One | 2017 Aug 10 | Zhuang R | doi: 10.1371/journal.pone.0182562 |
| 28077799 | KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis. | Oncotarget | 2017 Mar 28 | Du L | doi: 10.18632/oncotarget.14549. |
| 28538732 | CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. | Nature | 2017 Jun 1 | Kim J | doi: 10.1038/nature22359 |
| 27156442 | Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma. | J Thorac Oncol | 2016 Aug | Lococo F | doi: 10.1016/j.jtho.2016.04.020 |
| 27607580 | Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. | Cell Death Dis | 2016 Sep 8 | Klingbeil O | doi: 10.1038/cddis.2016.271. |
| 28899783 | Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras. | Biochem Biophys Res Commun | 2017 Nov 4 | Kharbanda A | doi: 10.1016/j.bbrc.2017.09.044 |
| 28068936 | Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. | BMC Cancer | 2017 Jan 9 | Nakayama I | doi: 10.1186/s12885-016-2994-6. |
| 27807105 | - | - | - | - | - |
| 28859058 | Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. | Br J Cancer | 2017 Oct 24 | Gollins S | doi: 10.1038/bjc.2017.294 |
| 28007627 | Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). | J Thorac Oncol | 2017 Apr | Schmid S | doi: 10.1016/j.jtho.2016.12.003 |
| 27215184 | KRas, ROS and the initiation of pancreatic cancer. | Small GTPases | 2017 Jan 2 | Storz P | doi: 10.1080/21541248.2016.1192714 |
| 28249840 | New Guideline on Managing Colorectal Cancer. | Cancer Discov | 2017 Apr | - | doi: 10.1158/2159-8290.CD-NB2017-030 |
| 28846180 | Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells. | Cancer Sci | 2017 Nov | Kutkowska J | doi: 10.1111/cas.13386 |
| 26989027 | Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. | Oncotarget | 2016 Apr 19 | Hsu HC | doi: 10.18632/oncotarget.8076. |
| 27012422 | L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells. | Free Radic Biol Med | 2016 Jun | Jung SA | doi: 10.1016/j.freeradbiomed.2016.03.009 |
| 28967920 | Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. | Nat Med | 2017 Nov | Romero R | doi: 10.1038/nm.4407 |
| 27468967 | Association of KRAS gene mutations with depression in older metastatic colorectal cancer patients. | Int Psychogeriatr | 2016 Dec | Zhou Y | - |
| 27835580 | KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer. | Oncotarget | 2016 Dec 6 | Cho YH | doi: 10.18632/oncotarget.13172. |
| 27602501 | Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers. | Oncotarget | 2016 Oct 18 | Fernandes MS | doi: 10.18632/oncotarget.11843. |
| 26786089 | KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion. | Ann Surg Oncol | 2016 Jun | Shindoh J | doi: 10.1245/s10434-016-5087-5 |
| 27435400 | IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. | Clin Cancer Res | 2017 Jan 15 | McMichael EL | doi: 10.1158/1078-0432.CCR-16-0004 |
| 27769041 | MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. | Oncotarget | 2016 Dec 20 | Wang YX | doi: 10.18632/oncotarget.12704. |
| 28030835 | Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress. | Oncotarget | 2017 Feb 7 | Li X | doi: 10.18632/oncotarget.14063. |
| 28032595 | Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells. | Oncotarget | 2017 Jan 31 | Rouhi A | doi: 10.18632/oncotarget.13841. |
| 26992209 | Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. | Oncotarget | 2016 Apr 26 | Lee B | doi: 10.18632/oncotarget.8074. |
| 27020587 | KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy. | Ann Surg Oncol | 2016 Aug | Chow OS | doi: 10.1245/s10434-016-5205-4 |
| 27517152 | A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer. | Oncotarget | 2016 Sep 6 | Du Y | doi: 10.18632/oncotarget.11170. |
| 27780929 | KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models. | Oncotarget | 2016 Nov 29 | Kenessey I | doi: 10.18632/oncotarget.12806. |
| 27705932 | KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. | Oncotarget | 2016 Nov 29 | Le Calvez-Kelm F | doi: 10.18632/oncotarget.12386. |
| 28167505 | Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network. | Mol Cancer Ther | 2017 May | Chatterjee S | doi: 10.1158/1535-7163.MCT-16-0677 |
| 28289161 | Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. | Mol Cancer Res | 2017 Jul | Yamaoka T | doi: 10.1158/1541-7786.MCR-16-0482 |
| 27494869 | miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression. | Oncotarget | 2016 Sep 20 | Ye YP | doi: 10.18632/oncotarget.11016. |
| 28407465 | KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. | Korean J Intern Med | 2017 May | Park S | doi: 10.3904/kjim.2015.299 |
| 28583095 | The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. | BMC Cancer | 2017 Jun 5 | Won DD | doi: 10.1186/s12885-017-3381-7. |
| 28450086 | KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy. | Pathology | 2017 Jun | Trisolini E | doi: 10.1016/j.pathol.2016.12.348 |
| 28150169 | KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer. | Clin Transl Oncol | 2017 Jul | Sullivan I | doi: 10.1007/s12094-017-1620-7 |
| 27911859 | KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer. | Oncotarget | 2017 Jan 10 | Renaud S | doi: 10.18632/oncotarget.13697. |
| 28749408 | Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer. | Int J Mol Sci | 2017 Jul 27 | Toda K | doi: 10.3390/ijms18081632. |
| 28677778 | Wildtype blocking pcr coupled with internal competitive amplified fragment improved the detection of rare mutation of KRAS. | Mol Med Rep | 2017 Sep | Peng J | doi: 10.3892/mmr.2017.6883 |
| 28797274 | The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka. | BMC Res Notes | 2017 Aug 10 | Sirisena ND | doi: 10.1186/s13104-017-2731-5. |
| 28216246 | Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. | Clin Colorectal Cancer | 2017 Sep | Tosi F | doi: 10.1016/j.clcc.2017.01.004 |
| 28901317 | k-RAS mutation and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer. | J Cancer Res Ther | 2017 | Zhou B | doi: 10.4103/jcrt.JCRT_468_17. |
| 29093617 | Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR. | World J Gastroenterol | 2017 Oct 21 | Olmedillas-López S | doi: 10.3748/wjg.v23.i39.7087. |
| 29364867 | Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. | Nature | 2018 Feb 1 | Mueller S | doi: 10.1038/nature25459 |
| 29104470 | Critical Role of p53 and K-ras in the Diagnosis of Early Colorectal Cancer: a One-year, Single-center Analysis. | Int J Med Sci | 2017 Sep 13 | Lu HY | doi: 10.7150/ijms.20538 |
| 28601386 | Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment. | Clin Lung Cancer | 2017 Nov | Bordi P | doi: 10.1016/j.cllc.2017.04.013 |
| 28544747 | K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. | Mol Oncol | 2017 Sep | Yeung Y | doi: 10.1002/1878-0261.12078 |
| 27892494 | Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes. | Sci Rep | 2016 Nov 28 | Dou Y | doi: 10.1038/srep37982. |
| 29851957 | KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex. | PLoS One | 2018 May 31 | Rao DD | doi: 10.1371/journal.pone.0193644 |
| 29610327 | Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk. | Proc Natl Acad Sci U S A | 2018 Apr 17 | Ntai I | doi: 10.1073/pnas.1716122115 |
| 28685592 | Investigation of correlation between mutational status in key EGFR signaling genes and prognosis of stage II colorectal cancer. | Future Oncol | 2017 Jul | Li L | doi: 10.2217/fon-2017-0040 |
| 29335867 | Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer? | Eur Radiol | 2018 May | Yang L | doi: 10.1007/s00330-017-5146-8 |
| 29207158 | Overexpression of miR-19a inhibits colorectal cancer angiogenesis by suppressing KRAS expression. | Oncol Rep | 2018 Feb | Chen M | doi: 10.3892/or.2017.6110 |
| 29764594 | [Research Progress of KRAS Mutation in Non-small Cell Lung Cancer]. | Zhongguo Fei Ai Za Zhi | 2018 May 20 | Liu L | doi: 10.3779/j.issn.1009-3419.2018.05.11. |
| 29066722 | BCL-XL directly modulates RAS signalling to favour cancer cell stemness. | Nat Commun | 2017 Oct 24 | Carne Trecesson S | doi: 10.1038/s41467-017-01079-1. |
| 29303908 | Progression of Chronic Pancreatitis to Pancreatic Cancer: Is There a Role of Gene Mutations as a Screening Tool? | Pancreas | 2018 Feb | Rashid S | doi: 10.1097/MPA.0000000000000975. |
| 30047791 | PPARγ-Mediated p21 Induction in Aerodigestive Preneoplastic Cell Lines. | Ann Otol Rhinol Laryngol | 2018 Oct | Miller WA | doi: 10.1177/0003489418787833 |
| 30037374 | [Association between EGFR, ALK and KRAS Gene Status and Synchronous Distant Organ Metastasis in Non-small Cell Lung Cancer]. | Zhongguo Fei Ai Za Zhi | 2018 Jul 20 | Gao G | doi: 10.3779/j.issn.1009-3419.2018.07.06. |
| 29263151 | KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment. | Cancer Res | 2018 Jan 1 | Dias Carvalho P | doi: 10.1158/0008-5472.CAN-17-2084 |
| 29321082 | Long Noncoding RNA ATB Promotes Proliferation, Migration, and Invasion in Bladder Cancer by Suppressing MicroRNA-126. | Oncol Res | 2018 Aug 23 | Zhai X | doi: 10.3727/096504018X15152072098476 |
| 28220783 | An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. | Nat Commun | 2017 Feb 21 | Vallejo A | doi: 10.1038/ncomms14294. |
| 29068469 | BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922. | Mol Carcinog | 2018 Feb | Wang CY | doi: 10.1002/mc.22755 |
| 28508873 | Mutant KRAS promotes malignant pleural effusion formation. | Nat Commun | 2017 May 16 | Agalioti T | doi: 10.1038/ncomms15205. |
| 29556349 | Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients. | Theranostics | 2018 Feb 12 | Li X | doi: 10.7150/thno.22502 |
| 30368666 | Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate. | J Cancer Res Clin Oncol | 2019 Jan | Kordiak J | doi: 10.1007/s00432-018-2779-1 |
| 29413054 | A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients. | Lung Cancer | 2018 Feb | Aran V | doi: 10.1016/j.lungcan.2017.12.005 |
| 30683863 | Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. | Nat Commun | 2019 Jan 25 | Cafri G | doi: 10.1038/s41467-019-08304-z. |
| 29547736 | The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis. | Mutat Res | 2018 May | Zou Y | doi: 10.1016/j.mrfmmm.2018.03.001 |
| 29116623 | KRAS Mutation in Gastric Cancer and Prognostication Associated with Microsatellite Instability Status. | Pathol Oncol Res | 2019 Jan | Polom K | doi: 10.1007/s12253-017-0348-6 |
| 30599853 | Genomics of non-small cell lung cancer (NSCLC): Association between CT-based imaging features and EGFR and K-RAS mutations in 122 patients-An external validation. | Eur J Radiol | 2019 Jan | Rizzo S | doi: 10.1016/j.ejrad.2018.11.032 |
| 29453361 | Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C. | Oncogene | 2018 May | Cannataro VL | doi: 10.1038/s41388-017-0105-z |
| 29559746 | Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway. | Oncogene | 2018 Jun | Chu PC | doi: 10.1038/s41388-018-0222-3 |
| 29786130 | RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases. | Ann Surg Oncol | 2018 Aug | Okuno M | doi: 10.1245/s10434-018-6517-3 |
| 28043144 | Association of EGFR and KRAS mutations with expression of p-AKT, DR5 and DcR1 in non-small cell lung cancer. | Neoplasma | 2017 | Zhao XD | doi: 10.4149/neo_2017_203. |
| 30467381 | Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasis. | Oncogene | 2019 Mar | Weng CC | doi: 10.1038/s41388-018-0575-7 |
| 30562355 | Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients. | PLoS One | 2018 Dec 18 | Damin F | doi: 10.1371/journal.pone.0207876 |
| 30361395 | Positive association of PIK3CA mutation with KRAS mutation but not BRAF mutation in colorectal cancer suggests co-selection is gene specific but not pathway specific. | J Clin Pathol | 2019 Mar | Susanti S | doi: 10.1136/jclinpath-2018-205483 |
| 29808006 | SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. | Nat Med | 2018 Jul | Mainardi S | doi: 10.1038/s41591-018-0023-9 |
| 29454587 | Comparison of CT radiogenomic and clinical characteristics between EGFR and KRAS mutations in lung adenocarcinomas. | Clin Radiol | 2018 Jun | Lv J | doi: 10.1016/j.crad.2018.01.009 |
